Search Results

< Back to the upcoming events page https://www.youtube.com/watch?v=x-7k7GDS2CU Some Topics Covered: Neuroendocrine Cancer, Newly Diagnosed Download Presentation Slides >>> ABOUT Being newly diagnosed with neuroendocrine cancer (NETs) can feel overwhelming. Many patients find themselves asking, “What exactly is neuroendocrine cancer, and how is it different from other cancers?” This webinar is designed to bring clarity, reassurance, and guidance during one of the most confusing stages of the NET journey. Join Dr. Osama MoSalem, medical oncologist at St. Luke’s in Kansas City , for a clear and compassionate overview of what every newly diagnosed NET patient should know. Dr. MoSalem will explain what neuroendocrine cancer is, why it behaves differently from more common cancers, and how its unique features influence diagnosis and treatment. This session will walk you through the most important early concepts, including: Grade and stage: what they mean and why they matter Key tests and scans used at diagnosis Treatment pathways , including when to consider surgery, medications, targeted therapies, radioligand therapy, or clinical trials Essential questions to ask your care team Practical first steps to help you feel more prepared and empowered Whether you’re newly diagnosed, supporting a loved one, or simply trying to better understand this disease, this webinar will provide a solid foundation to help you make informed decisions with greater clarity and confidence. ABOUT DR. OSAMA MOSALEM Medical Oncologist St. Luke's Health System Kansas City Osama MoSalem, MD is a board-certified hematologist and medical oncologist with Saint Luke’s Cancer Specialists in Kansas City, MO where he specializes in the care of adults with gastrointestinal (GI) cancers including neuroendocrine tumors. In addition to caring for patients, Dr. MoSalem has been involved in clinical research primarily focused on gastrointestinal cancers, neuroendocrine tumors and precision oncology. Dr MoSalem earned his medical degree from Cairo University, Egypt, residency training in internal medicine at Michigan State University, followed by fellowship training at the Mayo Clinic College of Medicine and Science in Jacksonville, Florida. Outside of medicine, Dr. MoSalem enjoys staying active, playing soccer, and spending time with his family. THANKS TO OUR SPONSORS T he opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by the Neuroendocrine Cancer Foundation or the sponsors of this program. The Neuroendocrine Cancer Foundation does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments.

< Back to the upcoming events page Back to the Conference Page 2026 Neuroendocrine Cancer Patient Conference SPEAKERS Chandana Banerjee, MD, MPA Associate Professor Department of Supportive Care Medicine, Hospice and Palliative Care Dean, Director and Designated Institutional Official, Graduate Medical Education, City of Hope Chandana Banerjee, M.D., M.P.A., HMDC, is the dean, director and designated institutional official for Graduate Medical Education at City of Hope ® . She is also an associate professor in the Department of Supportive Care Medicine , specializing in hospice and palliative care. She developed the City of Hope Hospice & Palliative Medicine Fellowship. She also established the Cancer Pain Rotation for Kaiser Permanente Los Angeles Hospice & Palliative Medicine Fellowship, which is now part of the core curriculum for the Kaiser Permanente Southern California Hospice & Palliative Medicine fellowship program. Dr. Banerjee also developed and directed the End of Life Symposium, which was first held at City of Hope in September 2019 and was endowed by Arthur Riggs, Ph.D. She is the physician lead for Schwartz Rounds at City of Hope and serves as chair on the End of Life Option Act Subcommittee. She is also a member of the Continuing Medical Education and the Ethics and Quality of Life committees. She is currently chair-elect of the American Academy of Hospice & Palliative Medicine's (AAHPM) Medical Aid in Dying Special Interest Group. She served as chair-elect, chair and past chair on the AAHPM Humanities and Spirituality Special Interest Group from March 2019-2022. She serves on AAHPM's Editorial Board for the publication AAHPM Quarterly and has served on the assembly's Abstract Review Board. She is a reviewer for evidence-based research articles in hospice and palliative care submitted to McMaster University in Canada. Dr. Banerjee has written and published numerous articles and book chapters and spoken at conferences nationally and internationally. She is the editor for an upcoming book by Springer Publishing's CTAR series exploring views on end-of-life care, death, burial and bereavement within different cultures and religions. She also sits on the board of directors for Compassion & Choices, an organization dedicated to end-of-life issues. Dr. Banerjee is a contributing member on the National Comprehensive Cancer Network Fatigue Panel. Her leadership activities in education include excellence in teaching, faculty development and mentoring, and curriculum and program development. Dr. Banerjee earned her undergraduate degree with an honors scholar designation from University of Connecticut. She received her master's degree in public administration from New York University and her medical degree from Saba University School of Medicine. She completed her residency in pediatrics and her fellowship in adult hospice and palliative medicine from Kaiser Permanente Los Angeles. She is also a Hospice Medical Director Certified. Dr. Banerjee was recently selected as a Health Equity Scholar into the prestigious Cambridge Health Alliance — Center for Health Equity Education & Advocacy Program’s 2021-2022 Cohort. Dr. Banerjee loves to write poetry and her first collection, "Ashen Leaves," was published in July 2020. Her second book of poems, "Neruda in Bed," was published in November 2021. Jennifer Chan, MD, MPH Medical Oncologist Dana-Farber Cancer Institute Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. She focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. Dr. Chan is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. She has been the principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. Dr. Chan is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and the current Vice President of NANETS. She serves on the National Comprehensive Center Network (NCCN) Neuroendocrine Tumors Guidelines Panel. Dr. Chan is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. Chandrikha Chandrasekharan, MBBS Medical Oncologist Clinical Associate Professor University of Texas MD Anderson Cancer Center Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at MD Anderson Cancer Center, where she has focused on neuroendocrine tumors and pancreatic cancer since January 2025. She is a dual board-certified physician in Medical Oncology and Palliative Medicine. Dr. Chandrasekharan earned her medical degree from Kilpauk Medical College in India. She completed her internal medicine residency at the University of Florida College of Medicine in Jacksonville, followed by a fellowship in Palliative Medicine at Mayo Clinic, Rochester. She then pursued a fellowship in Medical Oncology at LSU Shreveport, and further specialized in gastrointestinal malignancies with an additional year of training at Mayo Clinic, where she developed a strong interest in neuroendocrine tumors. Prior to joining MD Anderson, Dr. Chandrasekharan served for eight years as a Clinical Associate Professor at the University of Iowa. There, she co-led the gastrointestinal oncology program and treated a broad range of GI malignancies. From 2021 to 2022, she was Co-Director of the Clinical Core for the Neuroendocrine Tumor SPORE. She is an active member of the North American Neuroendocrine Tumor Society (NANETS), currently serving as Co-Chair of the NANETS Annual Symposium Planning Committee, and previously chaired the Regional Medical Education Committee. In addition to her clinical and academic work, Dr. Chandrasekharan is engaged in clinical trials and research focused on healthcare outcomes, health equity, and global oncology care. Jaydira Del Rivero, MD Endocrinologist & Medical Oncologist National Cancer Institute National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Delphine Chen, MD Nuclear Medicine Physician Director of Molecular Imaging and Therapy Professor, Clinical Research Division Fred Hutch Cancer Center Dr. Delphine L. Chen is a nuclear medicine physician-scientist with more than 20 years of broad clinical expertise in all types of positron emission tomography (PET) and nuclear medicine molecular imaging diagnostic tests and therapy. She is particularly interested in how molecular imaging can provide information about cancer behavior and affect treatment decisions. After graduating from the Washington University School of Medicine, Dr. Chen completed a residency in nuclear medicine at Barnes-Jewish Hospital and a fellowship in nuclear medicine at Washington University School of Medicine. Dr. Chen was the principal investigator in the first in-human trial of PARP radiotracers to predict which patients will respond to PARP inhibitors, now shown to be highly effective in BRCA mutation-driven breast cancers. Her research seeks to expand the field of nuclear medicine and find new diagnostic imaging and therapy agents for clinical trials, including focusing on how PARP radiotracers can be used to identify additional patients who may respond to anticancer drugs. In 2006, she received the Damon Runyon Cancer Research Foundation Clinical Investigator Award in support of her research into PET imaging, and in 2021, the Academy for Radiology and Biomedical Imaging Research named her a Distinguished Investigator. She has contributed to multiple publications and has more than 300 citations and is a member of the Institute for Prostate Cancer Research, a collaborative effort between Fred Hutch and UW Medicine. Dr. Chen is board-certified in nuclear medicine by the American Board of Nuclear Medicine. Callisia Clarke, MD, MS, FACS, FSSO Chief of Surgical Oncology Associate Professor of Surgery Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. In 2024 President Biden announced her appointment as a Member of the National Cancer Advisory Board. Dr. Clarke plays a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and helping advance breakthroughs to prevent, detect, and treat diseases like cancer. Udhayvir Singh Grewal, MBBS Medical Oncologist Emory Winship Cancer Institute Udhayvir S. Grewal, MD, is a gastrointestinal and neuroendocrine tumor (GI/NET) medical oncologist at the Winship Cancer Institute of Emory University and an Assistant Professor of Medical Oncology at the Emory University School of Medicine in Atlanta, Georgia. His research focuses on drug development and care-delivery innovations for patients with neuroendocrine tumors. Dr. Grewal serves on the North American Neuroendocrine Tumor Society (NANETS) Membership & Diversity Committee and the European Neuroendocrine Tumor Society (ENETS) Grade 3 NENs Task Force. After medical school at Government Medical College in Patiala, India, Dr. Grewal completed his internal medicine residency at LSU Health Sciences Center–Shreveport and a hematology/medical oncology fellowship at the University of Iowa Holden Comprehensive Cancer Center, where he also remains an active collaborator with the UIowa NET SPORE team. Thorvardur Halfdanarson, MD Hematologist, Oncologist Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is President Emeritus of the North American Neuroendocrine Tumor Society (NANETS) as well. Julie Hallet, MD, MSc, FRCSC, FACS, FSSO Surgical Oncologist, Odette Cancer Centre, Sunnybrook Health Sciences Centre Associate Professor of Surgery, University of Toronto Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. Andrew Hendifar, MD Medical Oncologist Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. Pamela Kunz, MD Gastrointestinal Oncologist Yale Medicine Dr. Pamela Kunz is a Professor of Medicine at Yale School of Medicine where she serves as the Division Chief of GI Medical Oncology and Director of the Center for GI Cancers at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She serves as the Editor-in-Chief of JCO Oncology Advances and has previously held other leadership roles in the field including member of the FDA’s Oncology Drug Advisory Committee, President of the North American Neuroendocrine Tumor Society, and Chair of the Neuroendocrine Tumor Taskforce of the NCI. She was awarded ‘Woman Oncologist of the Year’ in 2021 by Women Leaders in Oncology. X @PamelaKunzMD Daneng Li, MD Medical Oncologist City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. Sheila Lindsay, NP, MSN, RN Gastrointestinal Medical Oncology University of California San Francisco Sheila Lindsay is a nurse practitioner at the University of California San Francisco where she sees patients with neuroendocrine tumors and other gastrointestinal malignancies. She helps patients manage the side effects of cancer and its treatments. She also helps to educate patients on how to optimize their health and quality of life while undergoing therapy and during recovery. She is part of the multidisciplinary team at the Center for Neuroendocrine Tumors at UCSF where she works closely caring for patients undergoing therapies including PRRT. She earned her bachelor’s degree in nursing from Creighton University in Omaha, Nebraska followed by a master’s degree from the University of California San Francisco School of Nursing Adult Nurse Practitioner program. Josh Mailman, MBA President NorCal CarciNET Josh Mailman was diagnosed with PNET in 2007. Josh is an internationally recognized advocate for NET patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, Board Member and Treasure of the Neuroendocrine Tumor Research Foundation (NETRF), a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. He is currently the sole patient rights advocate for the Nuclear Regulatory Commission’s Advisory Committee for the Medical Use of Isotopes (ACMUI). Josh is also a member of National Cancer Institute’s GI Steering Committee and serves as co-chair of the Patient Advocate Steering Committee. In 2015, Josh was honored with the Warner Advocacy Award, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year, Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO) and was named SIO Patient Advocate of Year in 2010. Josh is a frequent and sought-after speaker for his passionate and highly informed perspective on how patients can effectively participate in the process of working with key stakeholders to improve treatments and advance progress for better quality of life and eventual cures. Erik Mittra, MD, PhD Nuclear Medicine Oregon Health & Science Health Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). Guillaume Pegna, MD Assistant Professor of Medicine Division of Hematology/Medical Oncology Oregon Health & Science University Dr. Pegna is a medical oncologist who specializes in the care of adults with neuroendocrine tumors (NETs). He is additionally interested and experienced in the management of rare tumors, including pheochromocytomas, paragangliomas and adrenocortical carcinomas as well as other gastrointestinal cancers. Dr. Pegna is actively involved with clinical trials and cancer research to improve survival and quality of life for cancer patients and to better understand the biology of these diseases. He specializes in the use of chemotherapy, immunotherapy and multidisciplinary approaches to cancer care. Dr. Pegna finds it rewarding to help patients understand their disease, providing treatment options based on each individual patient, and supporting them through their treatment journeys. Victoria Ramirez, LCSW Licensed Clinical Social Worker Victoria Ramirez, LCSW is a Licensed Clinical Social Worker with over 14 years of experience supporting individuals navigating cancer, chronic illness, grief, and major life transitions. She specializes in working with patients and families impacted by oncology diagnoses, as well as those coping with loss, anxiety, and unexpected life changes. Victoria earned her Master of Social Work from the University of Southern California and is licensed in California. Her therapeutic approach is integrative, drawing primarily from client-centered therapy and cognitive behavioral therapy (CBT) to meet each individual’s unique needs. She is known for creating a calm, supportive, and judgment-free environment where clients feel safe to explore their experiences. With a warm and empathetic style, Victoria collaborates with clients to set both short- and long-term goals, adapting them as needs evolve over time. She is deeply committed to helping individuals build resilience, gain clarity, and feel supported throughout their healing journey. Michael C. Soulen, MD, FSIR, FCIRSE Interventional Radiologist Penn Medicine Michael C. Soulen, MD FSIR FCIRSE is the Professor of Radiology and Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center and Director of Clinical Research in the Division of Interventional Radiology. His major clinical and research focus for the past 30 years has been image-guided cancer therapy (interventional oncology), with a specific focus on embolotherapy and ablative therapy of solid tumors in the liver and kidney. Animal research includes swine, rabbit, and rat models for liver-directed therapies, investigating novel embolic agents, novel ablation devices, and ultrasound-mediated drug delivery using novel drug-loaded microbubble contrast agents. Clinic trials focus on embolotherapies for primary liver cancers, liver metastases from colorectal and neuroendocrine tumors, and renal cell carcinomas. Current clinical investigations focus on synergy between locoregional and systemic therapies, including 1) pharmacologic modulation of the metabolic stress response under conditions of embolic ischemia; 2) IR therapies as immunostimulants combined with immune checkpoint inhibition, 3) radioembolization with radiosensitizing drugs; 4) serial biopsy for tumor cell culture, rapid drug screening, sequencing and testing in PDX mice, with the goal of personalized precision medicine; and 5) the first international randomized trial comparing embolotherapy techniques for neuroendocrine tumor liver metastases. Dr. Soulen received Research Mentor awards from the University of Pennsylvania Department of Radiology and the North American Neuroendocrine Tumor Society and the Gold Medal from the Society of Interventional Radiology. Jason Starr, DO Hematologist/Oncologist Mayo Clinic Dr. Starr grew up in South Florida and earned his medical degree at Lake Erie College of Osteopathic Medicine in Bradenton, Florida. He did his training at Mayo Clinic School of Graduate Medical Education in Jacksonville, where he completed his internship and residency in internal medicine, followed by a hematology/oncology fellowship. Dr. Starr has developed an expertise in treating gastrointestinal malignancies and has co-authored papers and book chapters on the subject. He has a special interest in neuroendocrine tumors and is committed to advancing the field through clinical research, namely through the development and enrollment of clinical trials. Dr. Starr is also passionate about education and is integrally involved with fellow education and well-being. He is board certified in internal medicine, hematology, and oncology. "The greatest joy of my career is the interaction and relationships I am able to have with my patients," says Dr. Starr. In his free time he enjoys and values spending time with his wife and children. He also enjoys exercise for fitness and stress relief. Dr. Starr is proud of his Mayo roots and feels strongly about Mayo Clinic's conviction to hope, faith, and science. Back to the Conference Page

Calls to Action Every question you’ve asked, every challenge you’ve faced, and every choice you’ve made along the way holds meaningful insight. Patients and caregivers don’t just navigate care — you influence it. Your voice helps researchers, clinicians, and advocates better understand what matters most, what’s working, and what must change. By sharing your perspectives, you play an active role in moving neuroendocrine cancer care forward. You help ensure that future treatment decisions, support resources, and research priorities reflect the real needs of the people living this journey every day. Your lived experience is powerful — and it deserves to be heard. Take action. Disclaimer: Some of the studies and opportunities listed on this page may be sponsored or supported by pharmaceutical or industry partners. These are shared to support research and improve understanding of neuroendocrine cancer. They are not intended as marketing or for the purpose of selling any product or service. Participation is always voluntary, and we encourage you to discuss any questions with your healthcare team. CURRENT OPPORTUNITIES NET Experience Survey If you are living with or caring for someone living with neuroendocrine tumors (NETs), we invite you to share your experiences through an online survey. While there is no compensation for completing this survey, your responses will help us better understand the needs of people living with NETs. The survey will take 3-5 minutes to complete, and your answers will remain anonymous. We thank you for considering participating in this survey. Your responses are impactful. Take the Survey Study by Researchers at the University of Alabama at Birmingham (IRB-300015226-002) February, 2026 Researchers at the University of Alabama at Birmingham (UAB) are conducting an anonymous, IRB-approved survey to better understand how patients experience conversations about cancer surgery, including whether what matters most to patients is addressed during treatment decision-making. The goal of this study is to help inform more patient-centered communication and improve how patients are supported when making treatment decisions. Important note: When asked to select the option that best reflects your primary tumor site, neuroendocrine cancer / neuroendocrine tumor (NET) / neuroendocrine carcinoma is not listed as a separate category. Please select “Other” and, in the open-text field, note “Neuroendocrine tumor” or “Neuroendocrine cancer.” People with all types of neuroendocrine cancers are welcome to participate, including well-differentiated NETs, neuroendocrine carcinoma, pheochromocytoma, and paraganglioma. Who can participate: Adults diagnosed with cancer within the past 2 years Have met with a surgeon to discuss possible cancer surgery Time commitment: About 10 minutes Anonymous and voluntary Your perspective can help improve patient-centered communication for future patients. Take the survey here: https://uab.co1.qualtrics.com/jfe/form/SV_1OmDi6x2VzojfmK Take the Survey CLOSED Diagnosed with Insulinoma? Market Research Opportunity November, 2025 We are seeking individuals diagnosed with insulinoma to participate in an important research study. The goal of this project is to better understand the real-life experiences of people living with insulinoma — especially how hypoglycemia affects daily life, routines, relationships, and well-being. What Participation Involves Participants will take part in a one-hour confidential interview with Mike Reilly, an experienced and independent market research professional with extensive knowledge of insulinoma. Mike is dedicated to creating a respectful, comfortable experience, and all information shared will remain strictly anonymous. Compensation and Donation As a thank-you for your time: - Participants will receive a $250 honorarium - OLG Research will donate an additional $100 to the Neuroendocrine Cancer Foundation for each completed interview Interested in Participating? Please contact Nicole Maurer at OLG Research: Email: nmaurer@olgresearch.com Phone: +1-973-575-0019 Email Could YOU be in Crinetics' Next Carcinoid Syndrome Patient Leadership Council? December, 2025 Your experiences matter—and they can help shape the future of treatment. NCF is sharing an opportunity to participate in the Crinetics Patient Leadership Council, a small group of patients and care partners who meet virtually throughout the year to share insights about living with rare disease. Council members provide input on the patient journey, treatment experiences, educational needs, and how clinical trials are designed and communicated. The Council will consist of 8–10 patients or care partners who meet virtually 3–4 times per year, with the possibility of additional meetings as needed. Members commit to a one-year term (with the option to extend to two years) and are compensated for their time. All conversations are respectful, confidential, and focused on ensuring patient perspectives guide meaningful progress. Interested in learning more or applying? This is a chance to turn your lived experience into impact and help improve care for others. Interested in learning more or applying? Visit the Crinetics PLC Page Download Flyer VOICE epNEC Care Partner Survey February, 2026 We invite you to take part in an online survey to better understand your role as a care partner/caregiver in supporting an individual with neuroendocrine carcinoma. We want to learn more about the challenges you encounter while providing care and the areas where care and support can be improved. If you are interested, please click on the link or scan the QR code below to enter your email address: https://s-hab.medefield.com/wix/p294869318978.aspx We’ll send you a short questionnaire to confirm your eligibility, along with an informed consent form that explains the study in more detail. If you qualify and choose to participate, you will be directed to the full survey. Upon completing the survey, you will receive an honorarium as a thank-you for your time and contribution. Please note: The survey will come from Paradigm Sample (invite@decipherinc.com ) within 2-3 days. Please keep an eye on your inbox and check your spam or junk folder just in case. Your email will be used solely for the purpose of sending the survey invitation and will be deleted after the study concludes. Your information will be kept strictly confidential. Thank you for considering taking part in this important study. Download Flyer VOICE epNEC Patient Survey November, 2025 People living with neuroendocrine carcinoma (epNEC) are invited to share their experiences through an online research survey. Patient insights will help inform future care, resources, and support for the neuroendocrine cancer community. If you are interested, click the link below (or scan the QR code) to enter your email address. You will receive a brief eligibility questionnaire and additional study details. If eligible, you will be invited to complete the full survey. Sign up here >>> Survey invitations will be sent from invite@decipherinc.com within 2–3 days. Please check your spam or junk folder if needed. Your email will be used only to send the survey invitation and will be deleted after the study concludes. Thank you for considering taking part in this important study. Download Flyer Have You been Treated With AlphaMedix™? November, 2025 We’re looking for patients who would like to share their experiences in a one-hour, one-on-one interview with a company that wants to better understand the patient journey. No preparation needed An opportunity to share your story Participants will be compensated at fair market value Your voice and experience matter! Interested in Participating? Please contact Lisa Yean, Director of Programs and Outreach at NCF: Email: Lisa@NCF.net Email

Newly Diagnosed PARA ESPAÑOL, HAGA CLIC AQUI You’ve just been told that you have Neuroendocrine Tumor, Neuroendocrine Cancer, or Carcinoid. You may be feeling panic, disbelief, despair or even a sense of relief to finally have a correct diagnosis. After those initial waves subside and you are thinking clearly again, the biggest question on your mind may be – “now what?” One important thing you can do is to take control by becoming your own advocate and leading your health team. Here is a beginner’s guide to NET that provides helpful facts and tips. SEVEN FACTS ABOUT NET 1. Neuroendocrine cancer is also known as neuroendocrine tumor, or NET. 2. NET is uncommon. Eight in 100,000 people are diagnosed per year in the United States. 3. NET can affect neuroendocrine cells throughout the body. 4. NET may be difficult to diagnose. 5. Some (but not all) NET patients have symptoms from their cancer. 6. The cause of NET is unknown. 7. Seeking the opinion of a NET specialist is important for all NET patients. 1. Neuroendocrine Cancer is also known as Neuroendocrine Tumor, or NET. It is pronounced NOOR-oh-EN-doh-krin TOO-mer and often abbreviated as NET. Hear the pronunciation . There are many terms or acronyms you may hear. Here are some of them: Neuroendocrine Neoplasm (NEN) is the official medical term often seen in medical literature such as the World Health Organization (WHO) classification of NEN. NEN includes both NET and Neuroendocrine Carcinoma (NEC). More aggressive Neuroendocrine Carcinoma (NEC) is treated differently than Neuroendocrine Tumors. Well-Differentiated and Low or Moderate Grade (G1/G2) NET tends to be slow growing, compared to High Grade (G3) NET or NEC which tends to be faster growing and Poorly Differentiated. Carcinoid is an old term meaning “cancer-like” that is falling out of favor because it is not accurate. NET is not cancer-like; it is cancer. Though some are localized (meaning it has not spread from where it originated from), many are malignant (meaning it has spread from where it originated from). You may still hear some physicians refer to NETs that originate from outside the pancreas such as the lung or small intestine as carcinoid tumors. Neuroendocrine Cancer is often used to refer to NENs (NET or NEC) by patient advocacy organizations as it spreads awareness to the fact that NET is a type of cancer and not benign as previously thought. Other terms you might hear refer to the primary tumor site (e.g., PNET or pancreatic NET) or the hormone that the tumor secretes (e.g., Insulinoma or VIPoma). 2. NET is a rare cancer. About 8 in 100,000 people are diagnosed annually in the United States. NET is considered rare by incidence, the number of patients diagnosed per year in the U.S. The prevalence of patients living with NET exceeds those living with stomach and pancreatic adenocarcinoma combined. Both the incidence and prevalence of NET are on the rise. 3. NET can affect neuroendocrine cells throughout the body. These are hormone-producing cells, most commonly found in the gastrointestinal system (stomach, small intestine, large intestine, rectum), the lung, pancreas or other parts of the body. NET often spreads (or metastasizes) from the primary site of origin to the lymph nodes, liver and bones. The tumors that have spread are called metastases. A Note About Prognosis: A common question we hear is, “How long do I have to live?” It is common for patients to report that their doctor told them that they had only months to live with the recommendation to “get their affairs in order.” In contrast, NET specialists will often say, “We don’t know how long you have.” The more you learn about NET, the more you will learn that prognosis is difficult to predict. NET is unpredictable, and each person’s case is unique, so it is typically difficult to predict a prognosis. Also, many of the statistics you might read are outdated. There have been many recent advances in NET research, which have led to earlier detection and more treatment options. As a result, patients are living longer with the disease. There are many in the NET community living with this disease for over a decade. 4. NET is a cancer that is difficult to diagnose. This is because not everyone with NET is symptomatic. For those who do have symptoms (less than half of all NET patients), these symptoms are vague and include flushing, diarrhea, nausea, abdominal cramping, bloating/gas and shortness of breath. 5. Some (but not all) NET patients have symptoms from their cancer. Typically, only those patients who have hormone-producing tumors called functional tumors have symptoms. For example, about 20-30% of people with small bowel (NETs) develop Carcinoid Syndrome (CS) with tumors produce serotonin. 6. The cause is unknown. People often wonder if they might have done something to cause their cancer. The answer is NO. Although there are a few types of NET that have a genetic correlation, most have no known cause. 7. Seeking the opinion of a NET specialist is important for NET patients. When most people are first diagnosed with neuroendocrine cancer, it is usually not by a NET specialist. Most patients end up seeking a second opinion with a NET expert, which may mean traveling outside of the area in which they live. Because NET is a rare disease, many doctors know little about it or the recent advances in diagnosis and treatment. A NET specialist can help guide your treatment plan. They can collaborate with your multidisciplinary doctors to manage your symptoms, monitor your disease and recommend treatments best suited for you. According to a large-scale survey of NET patients , those who received their care at a NET specialty center felt significantly more satisfied with their medical treatment and more knowledgeable than those who did not visit a NET specialty center. 1. Get organized NET VITALS is an ideal place to start. NET VITALS is a downloadable document to collect and keep the essential information about your specific NET disease. This comprehensive, curated list, contains what you and your healthcare professionals need to know about your neuroendocrine cancer. NET VITALS is a patient-physician communication tool, a “passport,” containing all the vital NET information in one location and simple to bring to your medical appointments. While it is not a medical document, it has been reviewed by NET specialists who agree that completing NET VITALS, as much as possible before their appointment, is helpful. Please note: NET VITALS is intended for informational and educational purposes only. LACNETS does not collect or store your information. It is for your personal use only. NET VITALS Helps: Educate you on what information is crucial to know about your NET disease. You organize, collect and compile this information into one comprehensive document that is easy to share with all healthcare professionals. Prepare you to ask relevant questions of your NET specialist for an optimal visit. Record Keeping Tips: Many people choose a way to organize their information such as a three-ring notebook or file folder. If you keep paper copies of labs, imaging reports, and pathology reports, consider scanning them so you have a digital copy as well. This not only makes your records easier to access, it also ensures that you do not lose your only paper copy! Download the Abridge app to record your healthcare visits and get transcriptions you can reveiw. To obtain second opinions, choosing an electronic system of record keeping on your computer or a cloud service can be helpful if you want to send information electronically. Some people track lab results on a spreadsheet to follow trends. Whatever method you choose, organization is key! You want to know where everything is stored. Information should be easy for you to access and share with your medical team when needed. NET VITALS is an ideal place to keep your vital NET information. After every scan, go to medical records or the film library and ask for a CD of the scan images for your records. We recommend requesting two copies, one for your NET specialist and one for second opinions or other members of your medical team. Never give away your only copy of any CD, report or document. After any biopsy or surgery, ask your doctor for the pathology report. These are often unavailable in your online patient portal, so you may need to request a copy. After any surgery or procedure, ask for the operative report or procedure report. These are often unavailable in your online patient portal, so you may need to request a copy. 2. Educate yourself on the disease: Learn to speak "NET" Watch this short (~5min) “What is NET?”video . It is great to share with family & friends to help them learn and understand more about your cancer. Watch this helpful introduction to NETs presentation by NET expert Dr. Pamela Kunz, as well as the “NETs 101” presentation by Dr. Sandy D. Kotiah, Medical Oncologist at Mercy Medical. This informative presentation, “What to Expect with a NET Expert Consultation” by Dr. Heloisa Soares at Huntsman Cancer Institute. The LACNETS webinar, “Sequencing of Neuroendocrine Tumor Treatments” with Dr. Eric Liu, General Surgeon & Neuroendocrine Specialist at Rocky Mountain Cancer Center. Check out Triage Cancer’s valuable organization resources: “Checklist: Getting Organized.” “Checklist to Avoid Financial Toxicity ” Cancer Rights Guide: “Navigating Employment, Insurance, & Finances” The National Comprehensive Cancer Network (NCCN) is an alliance of the leading cancer centers across the country that develop and publish up-to-date, evidence-based practice guidelines called NCCN Guidelines . Because these NET guidelines are recognized as the standard in cancer care, it is an essential resource in discussions with your medical team. It is also an excellent reference when dealing with insurance claims. Order your free Neuroendocrine Cancer Guide for patients and families from Neuroendocrine Tumor Research Foundation (NETRF). Download or request The Healing NET Foundation Navigating the NET Patient Journey peer-to-peer publication for patients and caregivers. Canadian Neuroendocrine Tumor Society (CNETS) has a downloadable Reference Guide for Patients and Families. The Global NET Patient Information Pack by the International Neuroendocrine Cancer Alliance (INCA) is available for download in 10 languages. Connect with and learn from others who are living with or have been affected by NET. Register for our Weekly Virtual Support Group every Wednesday from 12-1:30 PM Pacific Time. Subscribe to the LACNETS YouTube channel to find over 275 videos on various topics. 3. Find Support Support groups are often a rich source of educational meeting and resources for patients and their families. People often learn much from the experiences of others. Some report finding their NET specialist(s) because of attending a support group. Join our support community . We often hear people say, "I thought I was the only one with the disease." Connecting with others can help you feel less alone. Connect with a mentor. NETCONNECT connects you with another NET patient or caregiver for questions, support and more. 4. Find a NET Specialist Studies show that NET patients who are seen by a multidisciplinary team tend to have better outcomes. Typically, NET centers are able to diagnose and treat NET faster and more accurately. It is best to have a multidisciplinary approach where a team of NET specialists with different areas of expertise get together and review your case. This often takes place at a tumor board where your case is discussed and reviewed by several doctors including medical oncologists, endocrinologists, gastroenterologists, surgeons, radiologists, nuclear medicine doctors, and pathologists. Since patients are not allowed to be present, this video of a mock tumor board at a LACNETS conference gives you an idea of what one is like. How to Find a NET Specialist: Neuroendocrine Tumor Research Foundation (NETRF) is a good place to start. Many of the NET specialists (including oncologists, surgeons, endocrinologists, etc.) have been speakers at past NET patient conferences and meetings. Find and watch NET experts from our Video Library . You may find it helpful to “see” the doctor before your appointment. 5. Decide who will be your quarterback Patients often see many doctors with different areas of expertise. Some patients seek opinions from multiple NET experts as well. The important thing is finding a physician who you feel listens to and addresses your concerns, explains things in a way you understand, and provides access to the treatments you need. A collaborative relationship is important, both with you and the rest of your team. Once you have selected your multidisciplinary medical team, decide who will lead and call the shots. 6. Attend a NET patient education conference Learn about upcoming virtual and in-person conferences hosted by LACNETS and the broader NET Community. It is worthwhile to stay connected and interact with NET experts, patients, caregivers and those who serve the NET Community. Click here to read "Why Attend NET Patient Education Conference" 7. Breathe And last but not least, don’t forget to breathe. Stop to reflect and remember the reason we educate ourselves is to LIVE better. For most of us, living with NET is more like running a marathon than a sprint. Some feel a pressure to spend every waking minute learning about the disease so they don’t miss something that could mean the difference between life or death. For the majority of NET patients, that is simply not reality. It is just as important to take care of our emotional, mental and spiritual health as it is our physical health. If you’re feeling overwhelmed, it’s a good idea to take a break and do something that is life-giving and unrelated to cancer. Find the presence of mind to enjoy life’s simple pleasures like a walk on the beach, being in nature, gardening, seeing a movie, going to a museum or attending a concert. When you feel rested and ready to resume your education, come back to learn more about NET. It’s amazing how restorative taking just one minute to breathe can be. Click here to read "Breathe" blog post SEVEN TIPS FOR THE NEWLY-DIAGNOSED PATIENT 1. Get organized 2. Educate yourself on the disease: Learn to speak "NET" 3. Find support 4. Find a NET specialist 5. Decide who will be your quarterback 6. Attend a NET patient education conference 7. Breathe

Learn more about the NET experts presenting on various topics during the 2023 LACNETS Neuroendocrine Tumor Patient Conference. 2023 LACNETS Conference Speakers NETS 101: OVERVIEW OF NET TERMS & CONCEPTS AMAN CHAUHAN, MD Medical Oncologist, University of Miami Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer Institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. A CONVERSATION WITH THREE NET SURGEONS CALLISIA CLARKE, MD Surgical Oncologist, Medical College of Wisconsin Dr. Callisia N. Clarke completed her medical degree at the University of Cincinnati College of Medicine where she was elected to the Alpha Omega Alpha Honors Society. She completed a general surgery residency at the University of Cincinnati Medical Center in Cincinnati, Ohio in 2013 and a fellowship in Complex General Surgical Oncology at The University of Texas MD Anderson Cancer Center in 2016. She joined the faculty at the Medical College of Wisconsin in 2016 as an Associate Professor of Surgery in the Division of Surgical Oncology. Dr. Clarke specializes in hepato-pancreatic-biliary malignancies, melanoma and sarcoma, with her research efforts centered on epigenetic regulation of Neuroendocrine Tumors. She holds numerous leadership positions in national organizations including the American Hepato Pancreato-Biliary Association, the Association for Academic Surgery, the North American Neuroendocrine Tumor Society, and the Society of Surgical Oncology. ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. DANIEL ANAYA SAENZ, MD Surgical Oncologist, Moffitt Cancer Center Dr. Daniel Anaya is a Senior Member, Chief of GI Surgery and Head of Hepatobiliary Section in the Department of Gastrointestinal Oncology, at Moffitt Cancer Center. Dr. Anaya is a fellowship trained Surgical Oncologist with a particular focus on the surgical treatment of patients with liver malignancies (primary and metastatic) and neuroendocrine tumors. His academic interests focus on improving the quality of cancer care and implementing models to improve the delivery of care for patients with complex cancers. He is an expert in developing academic programs that facilitate the delivery of the highest quality of care, while also providing a framework to support research and innovation in the field of cancer and surgery. THE LATEST IN LIVER-DIRECTED THERAPY OSMAN AHMED, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. THE LATEST IN NET IMAGING NADINE MALLAK, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, MD is an Associate Professor of Diagnostic Radiology at Oregon Health and Science University (OHSU), in the divisions of Body Imaging, and Molecular Imaging and Therapy. She is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for neuroendocrine tumors and prostate cancer. THE LATEST IN PRRT CARINA MARI APARICI, MD Radiologist & Nuclear Medicine, Stanford University Health Care Mari Aparici, MD is a Clinical Professor in Radiology at Stanford University. She is a Nuclear Physician with residencies in both Europe (Barcelona) and US (Stanford), and with Molecular imaging fellowships from Stanford University. After her training, she joined the Faculty at UCSF where she became a Clinical Professor in Radiology. Dr Mari Aparici is a physician-scientist in the development of Molecular Imaging and therapies. She has more than 20 years of clinical and research experience in the field and now serves as the Director of the Targeted Radionuclide Therapy Program/Theragnostics Clinic at Stanford University. She has published more than 100 papers, serves as an editorial board member of reputed journals, is PI of NIH and non-NIH grants and serves as a member/chair of several committees at her University and Societies related to her medical specialty. THE LATEST IN SYSTEMIC TREATMENTS & CONSIDERATIONS FOR TREATMENT SEQUENCING PAMELA KUNZ, MD Medical Oncologist, Yale Cancer Center Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine and Director of the Center for Gastrointestinal at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with gastrointestinal (GI) malignancies and neuroendocrine tumors (NETs). She holds key leadership positions in the field including Chair of the Neuroendocrine Tumor Taskforce of the NCI and vice president of the North American Neuroendocrine Tumor Society. In addition, she has emerged as a leading voice for promoting gender equity in the medical workforce and serves as the Vice Chief for DEI for the Section of Medical Oncology at Yale. She was recently awarded the Woman Oncologist of the Year by Women leaders in Oncology. THE LATEST IN NET CLINICAL TRIALS SIMRON SINGH, MD Medical Oncologist, Sunnybrook Health Sciences Center Dr. Simron Singh is an Associate Professor of Medicine, at the University of Toronto and co-founder of the Susan Leslie Clinic for Neuroendocrine Cancers at the Odette Cancer Centre Sunnybrook Health Sciences Centre. In addition, he is a principal investigator and associate scientist with the Institute for Clinical Evaluative Sciences and Sunnybrook Research Institute. He completed his B. Sc as well as MD at University of Alberta in Edmonton, Alberta. He completed postgraduate training in Internal Medicine at Queens University in Kingston, Ontario, Canada and Medical Oncology at the University of Toronto. After completing his clinical training, Dr. Singh completed his Master's degree in Public Health from Harvard University in Boston, MA, USA. In 2013, Dr. Singh joined Cancer Care Ontario/Ontario Health (CCO/OH) as the Provincial Head, Person-Centred Care Strategy, responsible for the development and execution of CCO corporate strategic priority around person-centred care. He’s had numerous other board and administrative roles both at the national and international level. Dr. Singh is the symposium chair for the North American Neuroendocrine Tumor Society as well as the co-chair of the Commonwealth Neuroendocrine Tumour Group. He is the Canadian Clinical Trial group NET disease site group co-chair, as well as on the European Neuroendocrine Tumour Society advisory board. He currently is the co-chair of the Neuroendocrine Advisory Committee at Cancer Care Ontario which has been able to bring PRRT and Ga-68 imaging to Ontario. Dr. Singh is an internationally recognized clinical and research leader in the field of neuroendocrine cancers. He is a leader in health services research and system level quality improvement and measurement. Dr. Singh has been published in numerous high impact journals such as Lancet, Lancet Oncology, JAMA Oncology and the Journal of Clinical Oncology as lead or senior author. He has been the primary author of numerous guidelines to improve the care of NET patients. He holds a number of peer reviewed grants as well as clinical trial leadership positions. Dr. Singh has numerous international speaking invitations as well as leads a number of research and quality initiatives to improve the ongoing care of patients with cancer. CLINICAL TRIALS: WHY, WHAT & HOW JOSH MAILMAN, MBA President, NorCal CarciNET Josh Mailman was diagnosed with PNET in 2007. Josh is an internationally recognized advocate for NET patients as well as an advocate for integrative oncology and nuclear medicine and molecular imaging. He is the inaugural chair of the Society of Nuclear Medicine and Molecular Imaging’s (SNMMI) Patient Advocacy Advisory Board, Board Member and Treasure of the Neuroendocrine Tumor Research Foundation (NETRF), a member of The Education and Research Foundation for Nuclear Medicine and Molecular Imaging (ERF) Board, and president of NorCal CarciNET Community, one of the largest NET patient communities in the United States. He is currently the sole patient rights advocate for the Nuclear Regulatory Commission’s Advisory Committee for the Medical Use of Isotopes (ACMUI). Josh is also a member of National Cancer Institute’s GI Steering Committee and serves as co-chair of the Patient Advocate Steering Committee. In 2015, Josh was honored with the Warner Advocacy Award, given annually by Novartis Oncology Patient Advocacy and The NET Alliance. The award recognizes an individual for leadership and advocacy for neuroendocrine patients. In the same year, Josh was given the SNMMI’s President’s Award for his work on behalf of patients in the nuclear medicine field. Josh is a former executive board member of the Society for Integrative Oncology (SIO) and was named SIO Patient Advocate of Year in 2010. Josh is a frequent and sought-after speaker for his passionate and highly informed perspective on how patients can effectively participate in the process of working with key stakeholders to improve treatments and advance progress for better quality of life and eventual cures. MODERATORS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. MARY DONLEVY LACNETS Board member and NET Patient Advocate Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. << Go back to the 2023 Annual Conference Page

Surgery for NETs Resources EDUCATIONAL WEBINARS "What Matters About Liver Surgery" with Dr. Hallet Watch here "Evolving Management of NET Liver Metastases" with Dr. Singh Watch here "Understanding Surgery for Liver NETs" with Dr. Clarke Watch here "Understanding Carcinoid Crisis" with Dr. Hallet Watch here "A Conversation with Three NET Surgeons" with Dr. Clarke, Dr. Gangi and Dr. Anaya Watch 'A Conversation with Three NET Surgeons' featuring Dr. Callisia Clarke, Dr. Alexandra Gangi and Dr. Daniel Anaya Saenz. This presentation is part of the 2023 LACNETS Neuroendocrine Tumor Patient Education Conference held on June 17, 2023. Watch here "NET Surgery: Making Decisions & Preparing for Surgery" with Callisia Clarke, MD Is surgery the right treatment option for you? Dr. Callisia Clarke joined us for our annual patient conference to address surgery for NETs including decision-making & preparing for surgery. Watch here "Patient Story: How to Prepare for Surgery" NET patient Julie’s “show and tell” of tips, tricks, and specific items she found useful during her hospital stay and recovery at home. Click here for a list of the items Julie mentioned in this video. Watch here Click here for our full surgery video playlist. PODCAST EPISODE 27: WHAT TO KNOW ABOUT NEUROENDOCRINE TUMOR LIVER METASTASES What do you call NETs in the liver? How often do NETs spread and what causes NETs to spread? How do you determine if surgery is an option? Dr Xavier Keutgen from University of Chicago brings clarity to NET tumors found in the liver and describes how surgery fits in with other treatments for metastatic NETs. LISTEN NOW SURGERY FOR NETS To cut or not to cut? A crossroad many neuroendocrine cancer patients are faced with along their journey. NET surgeon Dr. Gagandeep Singh of City of Hope answers the top 10 surgery questions for NETs. LISTEN NOW KEY CONSIDERATIONS FOR NET SURGERY How do surgeons decide the type, extent, and approach of NET surgery? NET surgeon Dr. Alexandra Gangi of Cedars-Sinai answers 10 common questions about what to expect before, during, and after NET surgery. Gain insight on preparing for surgery and what is important for your surgeon to know about your recovery goals. Dr. Gangi’s comprehensive approach illustrates why surgeons are an integral part of your NET medical team. LISTEN NOW ADDITIONAL SURGERY RESOURCES NET Quiz - Test Your Knowledge! How much do you really know about surgery and international radiology for NETs? Test your NET knowledge by taking this six question quiz based off of the NETWise podcast episode #3: “Surgery and Interventional Radiology for NETs.” Take the Quiz Blog Post - Practical Tips for Patients Preparing for Surgery Many NET patients undergo surgery as part of their treatment course. While their medical team might have specific preparation instructions, patients often wonder about practical concerns like how to plan, what to pack, and how to prepare the home... Read the Blogpost

Join us at the 2023 LACNETS NET Cancer Day Symposium in Santa Monica, California: - Well-rounded agenda featuring NET experts from the medical community and patient stories. - Learn about active clinical trials and hear from patients who are participating in clinical trials. - Celebrate World NET Cancer Day with inspiring, original music by a NET patient. 2023 NET Cancer Day Symposium • Santa Monica, CA • @LACNETS 2023 NET Cancer Day Symposium • Santa Monica, CA • @LACNETS Play Video Share Whole Channel This Video Facebook Twitter Pinterest Tumblr Copy Link Link Copied Now Playing "NETS 101" • Jaydira Del Rivero, MD • 2023 NET Cancer Day Symposium @NCFCancer 25:45 Play Video Now Playing "Surgical Treatments" • Alexandra Gangi, MD • 2023 NET Cancer Day Symposium @NCFCancer 20:38 Play Video Now Playing "Medical Treatments" • Andrew Hendifar, MD • 2023 NET Cancer Day Symposium @NCFCancer 16:08 Play Video Agenda Speaker Bios OUR SPONSORS Agenda Read 2023 NCD: A Memorable Celebration ABOUT Join us at the 2023 LACNETS NET Cancer Day Symposium in Santa Monica, California: Well-rounded agenda featuring NET experts from the medical community and patient stories. Learn about hot topics including surgery, medical treatments, PRRT, and clinical trials. Celebrate NET Cancer Day with inspiring, original music by a NET patient. Connect with NET experts, patients and caregivers. No cost to attend. This event is made possible by the generosity of donors and sponsors. AGEN DA (Subject to change) Speakers SPEAKERS THE LATEST IN PRRT MARTIN AUERBACH, MD Nuclear Medicine, UCLA Dr. Allen-Auerbach is the Medical Director of UCLA Nuclear Medicine and Clinical Professor in Nuclear Medicine, Division of Pharmacology, at the David Geffen School of Medicine at UCLA. Apart from serving as attending physician in Nuclear Medicine, active research includes clinical studies investigating the role of molecular imaging with PET/CT to gain insights into malignant disease processes and as well as applications of Nuclear Medicine for the treatment of cancer. NETS 101 & OPPORTUNITIES TO ACCESS NET RESOURCES AND CLINICAL TRIALS JAYDIRA DEL RIVERO, MD Endocrinologist and Oncologist National Cancer Institute Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. SURGICAL TREATMENTS ALEXANDRA GANGI, MD Surgical Oncologist, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. The Nuts & Bolts of PRRT LINDA (LINDY) GARDNER, MSN, RN, VA-BC Lead Nurse, Nuclear Medicine, UCLA Health Lindy has over two decades of Interventional Radiology experience prior to transitioning over to Nuclear Medicine in March of 2017. She obtained her RN qualification in 1993 from John Moores University of Liverpool, (LJMU) United Kingdom, she is a graduate from the University Of Dundee, Scotland where she received her Bachelors, and Master’s of Science in Nursing. In her Nuclear Medicine role Lindy is the lead nurse for the Peptide Receptor Radionuclide Therapy (PRRT) program, from the expanded access program (EAP) thru to the FDA approved commercial program. She has presented this program to a national and international audience; her skills are utilized as an expert liaison for institutions commencing the PRRT program, focusing on the patient experience, education, and therapy administration. Lindy is the nursing pillar lead for The International Center for Precision Oncology foundation (ICPO), with her focus on education, support and navigation for the NET patient journey. She is also the lead nurse for Radio-Ligand Therapy (RLT) for prostate cancer within Theranostics at UCLA, covering both clinical application and research. Lindy is a member of the Association for Radiologic and Imaging Nursing (ARIN), and the Association for Vascular Access (AVA), holding her board certification in vascular access (VACC). She sits as a member on The Healing NET Scientific Advisory Committee. CLINICAL TRIALS 101 J. RANDOLPH HECHT, MD Medical Oncologist, UCLA Health Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. MEDICAL TREATMENTS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. HOW PATIENT PREFERENCES IMPACT TREATMENT DECISIONS DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. PIANO CONCERT TOM BAJORAS Composer & NET Patient Tom Bajoras began playing piano and composing music as a young child growing up in Pennsylvania. Music has been his constant companion ever since, leading him to Los Angeles, where he pursued dual careers in music and music technology. In 1991 he founded a company that develops custom software for the entertainment industry. In January 2015 Tom's life took a sudden detour when he was diagnosed with metastatic pancreatic NET. This prompted an early retirement from his software company, which allowed him to work full-time in his home studio. He currently records his own music, as well as producing music for other artists and spoken-word projects such as audiobooks and podcasts. In 2018 Tom released a CD, Surprised By Beauty, a collection of music he wrote during the first two years of his journey with NET. Since then he has written a wide variety of music, videos, and poetry, all focused on discovering beauty in unexpected places. He finds joy through sharing his music and stories of hope in small, intimate concerts. When not creating in his studio or performing for audiences, Tom enjoys travel, theater, and hiking with his wife, Lisa, and their rescue dog, Skyler. THANKS TO OUR SPONSORS Up The information provided is for educational purposes only and does not substitute for medical advice. Talk to your medical team if you have any questions or concerns about your individual care and treatment. The opinions expressed in this program are those of the speakers and do not represent the opinion of LACNETS.

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2025 Conference Speakers << Go back to the 2025 Annual Conference Page Overview of Neuroendocrine Cancer What is Neuroendocrine Cancer? Bhavana Konda, MD, MPH Medical Oncologist, Ohio State University Comprehensive Cancer Center (OSUCCC) Dr. Bhavana Konda is a Medical Oncologist with expertise in neuroendocrine tumors and endocrine-related cancers. She leads the Neuroendocrine Tumor and Endocrine Medical Oncology Section at the Ohio State University Comprehensive Cancer Center. Her research is dedicated to advancing treatment options to patients with these rare cancers through innovative clinical trials. Understanding Matters About Biomarkers & Blood Tests Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson is President Emeritus of the North American Neuroendocrine Tumor Society (NANETS) as well. What Matters About Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. What Matters About Symptom Management Vineeth Sukrithan, MD Medical Oncologist, Ohio State University Comprehensive Cancer Center (OSUCCC) Dr. Vineeth Sukrithan is a medical oncologist who specializes in the study and treatment of neuroendocrine cancer, thyroid cancer and adrenocortical cancer. He utilizes traditional chemotherapy, molecularly targeted oral medications, novel immunotherapy and peptide-receptor radiotherapies in the treatment of these unique cancers. As a comprehensive cancer center, the OSUCCC – James has unrivaled experience and expertise in the treatment of neuroendocrine, thyroid and adrenal tumors. Their world-renowned faculty are leaders in the study and treatments of these rare cancers, and as such, they are able to provide their patients with options beyond standard therapies that may not be available anywhere else. The strong focus on translational research at The James means that the treatment breakthroughs of tomorrow are being discovered in their laboratories today. Dr. Sukrithan is part of a tight-knit team of surgical oncologists, radiation oncologists and interventional radiologists who work together to provide cutting-edge care for our patients with neuroendocrine tumors. In addition to his clinical work, Dr. Sukrithan is a member of the Translational Therapeutics Program at the OSUCCC – James and the co-director of the Adrenal Tumor Clinic. He was recently selected to lead an externally funded effort through the International Thyroid Oncology Group to operationalize a multi-institutional registry database for patients with medullary thyroid cancer. Dr. Sukrithan also serves as an assistant professor in the Division of Medical Oncology at The Ohio State University and has completed postdoctoral fellowships in clinical research at Johns Hopkins University. His research has been published in numerous peer-reviewed journals, including Cancer Research, American Journal of Clinical Oncology and Clinical Lung Cancer. As every individual’s cancer is molecularly unique in countless ways, Dr. Sukrithan believes in tailoring therapies to the individual with the precision made available through cutting-edge scientific research. He feels it is a privilege to make a difference in the lives of patients as we work together to achieve a cancer-free world. Surgery & Local Regional Therapies What Matters About Liver Surgery Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. What Matters About Liver-Directed Therapy Alejandro Gabutti, MD Interventional Radiologist, National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) University Hospital and National Reference Center for Liver Diseases Dr. Alejandro Gabutti, born in southern Mexico and moved to Mexico City for medical school. He received his medical degree from the UNAM (National University of Mexico) in 2008. After a year working as a general doctor in the mountain region of Chiapas, Mexico, he decided to continue his medical education as a Radiologist. By the year 2006 Alejandro was accepted in the INCMNSZ and completed a 4-year radiology program. Since the very beginning during his radiology training Alejandro showed a special interest in the interventional radiology procedures. He successfully completed a two-year interventional radiology fellowship at the INCMNSZ. At the conclusion of his fellowship, Alejandro was hired as part of the INCMNSZ radiology staff. In 2019 Dr. Gabutti moved to Milan Italy and completed a 1-year internship at the Istituto Nazionale dei Tumori, with special emphasis in oncological liver directed therapies. By his return to Mexico, Alejandro continues working as an Interventional Radiologist at the INCMSNZ, became the Interventional Radiology program professor (UNAM) and keeps working to improve liver malignancies imaging and treatments. Expert Panel: What Matters Most in Making Decisions About Surgery & Local Regional Therapies Daneng Li, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. William C. Chen, MD Radiation Oncologist, University of California San Francisco Dr. William C. Chen is a radiation oncologist and translational researcher. Dr. Chen received his undergraduate degree from Johns Hopkins University and completed medical school at the University of California, San Francisco. He completed his internal medicine preliminary internship at Kaiser San Francisco, followed by a residency in Radiation Oncology at UCSF. He is a Chan Zuckerburg Biohub Physician Scientist Fellow and a Helen Diller Family Cancer Center Physician Scientist Program in Clinical Oncology (PSPCO) Fellow. His research focuses on biomarker development, informatics, and clinical trial development with a focus on meningiomas and other malignancies of the central nervous system and beyond. Medical Management & Sequencing Treatments What Matters About Systemic Treatments Jennifer Chan, MD, MPH Medical Oncologist, Dana-Farber Cancer Institute Jennifer Chan, MD, MPH is an Associate Professor of Medicine at Harvard Medical School and Institute Physician in the Division of Medical Oncology at Dana-Farber Cancer Institute in Boston, MA. Dr. Chan focuses her clinical practice on the care of patients with neuroendocrine tumors and gastrointestinal cancers. She is the Director of the Program in Neuroendocrine and Carcinoid Tumors and Clinical Director for the Gastrointestinal Cancer Center at the Dana-Farber/Brigham and Women's Cancer Center. Dr. Chan has been principal investigator of multiple clinical trials investigating novel therapies for neuroendocrine tumors and has been involved in studies examining factors associated with clinical outcomes in patients with neuroendocrine tumors. She is a past chair of the Guidelines Committee of the North American Neuroendocrine Tumor Society (NANETS) and President of NANETS. Dr. Chan serves on the National Comprehensive Cancer Network (NCCN) Neuroendocrine Tumors Guidelines Panel. She is a member of the Neuroendocrine Tumor Taskforce of the National Cancer Institute and the Board of Directors of NANETS. What Matters About PRRT: What is PRRT & How Does It Work? Cecilia Carreras Velázquez Nuclear Medicine, Hospital Ángeles Lomas Dr. Cecilia Carreras Velázquez is a board-certified specialist in Nuclear Medicine and Molecular Imaging, based in Mexico City. Graduated with honors from Centro Médico ABC (UNAM) in 2010 and completed a fellowship in Molecular Imaging in 2011. From 2012 to 2024, she served as Head of the Nuclear Medicine and PET/CT Department at Hospital Angeles Lomas, where she led the integration of advanced technology and the expansion of radionuclide-based diagnostic and therapeutic services. Pioneer in Mexico in implementing Lutetium-177 therapy for patients with Neuroendocrine Tumors and metastatic prostate cancer. In June 2024, Dr. Carreras assumed the position of Medical Director of Nuclear Medicine at the National Center for Radiology and Imaging within the Angeles Health System Hospitals in Mexico. Dr. Carreras has international experience, having collaborated with the research team at PET-Zentrum of Zentralklinik Bad Berka in Germany, focused on radionuclide therapies for neuroendocrine tumors. Since 2020, she has been a member of the Patient Safety and Quality Committee at Hospital Angeles Lomas, and in 2022, she was appointed Mexico Ambassador for the Oncidium Foundation, advocating for innovations in cancer treatment through nuclear medicine. For over a decade, she has actively participated in educational initiatives, specialty dissemination efforts, and patient-focused forums to enhance understanding and access to nuclear medicine advancements. What Matters About PRRT: Preventing and Managing Toxicities & Latest Advances Aman Chauhan, MD Medical Oncologist, University of Miami Health System Aman Chauhan, MD, earned his medical degree from the Kasturba Medical College in Manipal, Karnataka, India, followed by a dual residency in internal medicine and pediatrics at Louisiana State University in New Orleans. Dr. Chauhan completed his fellowship in hematology and oncology at the University of Kentucky, especially focusing on neuroendocrine tumor (NETs). Additionally, Dr. Chauhan completed a Cancer Therapy Evaluation Program (CTEP) physician externship at the National Cancer institute (NCI) that focused on designing clinical trials and clinical research projects. His clinical interests include treating NETs, including carcinoid tumors, high-grade neuroendocrine carcinomas, and small and large cell neuroendocrine carcinoma. Dr Chauhan leads the University of Miami Neuroendocrine Cancer Program and co-leads Sylvester Theranostics Drug Development Program. He is national principal investigator on several investigator initiated neuroendocrine cancer clinical trials. He has authored over 70 scientific publications and book chapters and has received a career development award from NCI CTEP. Dr Chauhan also serves on AJCC and ASCO NET guideline committees and is an active member of NANETS communication committee. Dr. Chauhan is board certified in internal medicine and medical oncology. He is a member of the American Society of Clinical Oncology as well as the American Association of Cancer Research and the North American Neuroendocrine Tumor Society. What Matters About Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including past President of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. Dr. Kunz was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021. Dr. Kunz was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity and received the 2024 'Distinguished Mentor Award' by the North American Neuroendocrine Tumor Society. X @PamelaKunzMD Expert Panel: What Matters Most in Making Decisions About Systemic Therapies & Sequencing Treatments J. Randolph Hecht, MD Medical Oncologist, UCLA Health Dr. Hecht is a Professor of Clinical Medicine in the David Geffen School of Medicine at UCLA School of Medicine. He holds the Carol and Saul Rosenzweig Chair for Cancer Therapies Development and is the Director of the UCLA Gastrointestinal Oncology Program. Dr. Hecht attended medical school at Eastern Virginia Medical School. He took his internal medicine residency at Northwestern and completed fellowships in gastroenterology research at the University of Chicago, and in gastroenterology and medical oncology at UCLA. Dr. Hecht is an internationally known clinical and translational researcher in the field of gastrointestinal cancers. He has published widely on the molecular biology, early detection, and treatment of gastrointestinal malignancies. He has lead and is currently directing small trials with new molecules as well as large international randomized trials. Current ongoing research includes preclinical models of therapy with biological agents, early studies with gene therapy vectors and tyrosine kinase inhibitors, and leading phase II and phase III trials with novel agents. Alexandra Gangi, MD Division Director of Surgical Oncology, Cedars-Sinai Medical Center Dr. Alexandra Gangi is a board-certified surgical oncologist at Cedars-Sinai Medical Center in Los Angeles. Dr. Gangi completed a general surgical residency at Cedars-Sinai and completed her surgical oncology fellowship at the H. Lee Moffitt Cancer Center in Tampa, Florida. She currently serves as the Division Director of Surgical Oncology and Director of the Gastrointestinal Tumor and Cancer Regional Therapies Programs with specialization in Pancreatic and GI Neuroendocrine tumors, Metastatic colorectal cancer, and Peritoneal Surface Malignancies. Her research focuses on understanding GEPNET heterogeneity between and within tumors subtypes and mechanisms of chemotherapy induced liver injury. Erik Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). David B. Zhen, MD Medical Oncologist, Fred Hutch Cancer Center Dr. David Zhen is a medical oncologist who specializes in treating patients with gastrointestinal cancers. His research centers around the development of clinical trials evaluating new therapies and combination approaches for the treatment of patients with gastrointestinal cancers, particularly pancreatic and gastroesophageal cancers. He is also conducting research to understand the interactions of the immune system in gastrointestinal cancers and how this can be manipulated to improve upon the response to immunotherapy drugs called checkpoint inhibitors, which block a braking system that cancers use to tamp down the immune response. Moderators: MARY DONLEVY NCF Board member and NET Patient Advocate Mary Donlevy joined the NCF Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Andrew Hendifar, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. << Go back to the 2025 Annual Conference Page

Learn more about the NET experts presenting on various topics during the 2024 LACNETS Neuroendocrine Tumor Patient Conference. 2024 LACNETS Conference Speakers Understanding NET Diagnosis: The Work-Up & What You Need to Know About Your NETs Chandrikha Chandrasekharan, MBBS Medical Oncologist, University of Iowa Dr. Chandrikha Chandrasekharan is a Clinical Associate Professor at University of Iowa. She did her initial medical training in India at Kilpauk Medical College. She moved to the USA to complete her internal medicine residency at University of Florida College of Medicine at Jacksonville. Dr. Chandrasekharan is board certified in Medical Oncology and Palliative Medicine. After completing medical oncology fellowship at LSU Shreveport, she pursued an additional year of advanced oncology training in gastrointestinal malignancies at Mayo Clinic. Dr. Chandrasekharan's clinical practice and research interests include all gastrointestinal malignancies with a focus on neuroendocrine tumors. Understanding NET Scans Nadine Mallak, MD Radiologist & Nuclear Medicine, Oregon Health & Science University Nadine Mallak, M.D. is a double boarded Associate Professor of Diagnostic Radiology at OHSU, in the divisions of Body Imaging, and Molecular Imaging & Therapy. She received her M.D. degree from Saint Joseph University Medical School in Beirut, Lebanon, followed by a Diagnostic Radiology residency at Hotel Dieu de France, Beirut. Subsequently, she finished fellowships in Neuroradiology and Abdominal Imaging, and a residency in Nuclear Medicine at the University of Iowa Hospitals and Clinics. Dr. Mallak is the clinical director of the PET/MRI program at OHSU. The scope of her clinical practice encompasses all aspects of molecular imaging and therapy, in addition to abdominal and pelvic imaging with modalities including ultrasound, CT, and MRI. Her research interests focus on molecular and hybrid imaging, particularly for prostate cancer, neuroendocrine tumors and pheochromocytoma/paraganglioma. In addition to her research projects, she’s passionate about education. She was voted by the radiology residents "outstanding teacher of the year" for the year 2019-2020, and by the graduating senior residents “outstanding board reviewer” for the year 2021-2022 In her free time, she enjoys painting, mostly with acrylic and watercolors, reading, hiking, and exploring the gorgeous nature in the Pacific Northwest. Understanding Surgery for Liver NETs Callisia Clarke, MD Surgical Oncologist, Medical College of Wisconsin Dr. Clarke is Chief of Surgical Oncology and Associate Professor of Surgery at the Medical College of Wisconsin with a focus on tumors of the upper gastrointestinal tract, sarcomas, melanomas and regional therapies for advanced malignancies. She specializes in hepato-pancreatic-biliary malignancies, primary and metastatic neuroendocrine tumors, melanoma and sarcoma. Her research efforts focus on personalized cancer care and targeted approaches in pancreatic neuroendocrine tumors. Dr. Clarke also serves on the Executive Committee of the Association for Academic Surgery and is the Chair of the North American Neuroendocrine Tumor Society (NANETS) Mentoring and Early Career Development Committee. President Biden recently announced she will be appointed as a Member of the National Cancer Advisory Board. Dr. Clarke will play a key role in guiding the Director of the National Cancer Institute in setting the course for the national cancer research program and help advance breakthroughs to prevent, detect, and treat diseases like cancer. Understanding Carcinoid Crisis Julie Hallet, MD, MSc., FRCSC Surgical Oncologist, Sunnybrook Health Sciences Center Dr. Hallet is an Associate Professor of Surgery at the University of Toronto and a Surgical Oncologist with a clinical practice devoted to hepato-biliary, pancreatic and upper gastrointestinal malignancies at the Odette Cancer Centre - Sunnybrook Health Sciences Centre. Her practice further focuses on neuroendocrine tumors as part of the Susan Leslie Multidisciplinary Clinic for Neuroendocrine Tumors, as well as minimally invasive therapies for cancer treatment. She completed general surgery residency and MSc in clinical epidemiology at Université Laval in Québec City, followed by a Surgical Oncology and hepato-pancreatico-biliary clinical fellowship at the University of Toronto, and additional training in advanced minimally invasive surgery at the Institut de recherche contre les cancers de l’appareil digestif (IRCAD) in Strasbourg, France. Dr. Hallet holds leadership roles in National and International societies. Among those roles, she serves as the Vice-Chair of the Hepato-Pancreatico-Biliary Disease Site Group of the Society of Surgical Oncology, the Chair of the Early Career Group the International Hepato-Pancreatico-Biliary Association, and a member of the Guidelines Committee of the North American Neuroendocrine Tumors Society, as well as on the executive committees of the Canadian Society of Surgical Oncology and the Canadian Hepato-Pancreato-Biliary Association. She is a founding member of the Society of Surgical Ergonomics for which she also chairs the Research and Applied Ergonomics Committee. She also is Associate Section Editor for the Annals of Surgical Oncology, and is part of the Editorial Board of HPB, the World Journal of Surgery, and the British Journal of Surgery. Dr. Hallet’s research focuses on health services research to examine processes of care and outcomes in oncology, with a focus on patient-centred and patient-reported outcomes. To support her research, she has received over $10 millions in operating grants, including from the Canadian Institutes of Health Research and the Ontario Institute of Cancer Research. Dr. Hallet has over 200 peer-reviewed publications, including high-impact papers in JAMA Surgery, JAMA Oncology, the Journal of the NCCN, and Annals of Surgery. Understanding Liver-Directed Therapy Michael Soulen, MD FSIR FCIRSE Interventional Radiologist, University of Pennsylvania Michael C. Soulen, MD FSIR FCIRSE is the Professor of Radiology and Director of Interventional Oncology at the University of Pennsylvania Abramson Cancer Center and Director of Clinical Research in the Division of Interventional Radiology. His major clinical and research focus for the past 30 years has been image-guided cancer therapy (interventional oncology), with a specific focus on embolotherapy and ablative therapy of solid tumors in the liver and kidney. Animal research includes swine, rabbit, and rat models for liver-directed therapies, investigating novel embolic agents, novel ablation devices, and ultrasound-mediated drug delivery using novel drug-loaded microbubble contrast agents. Clinic trials focus on embolotherapies for primary liver cancers, liver metastases from colorectal and neuroendocrine tumors, and renal cell carcinomas. Current clinical investigations focus on synergy between locoregional and systemic therapies, including 1) pharmacologic modulation of the metabolic stress response under conditions of embolic ischemia; 2) IR therapies as immunostimulants combined with immune checkpoint inhibition, 3) radioembolization with radiosensitizing drugs; 4) serial biopsy for tumor cell culture, rapid drug screening, sequencing and testing in PDX mice, with the goal of personalized precision medicine; and 5) the first international randomized trial comparing embolotherapy techniques for neuroendocrine tumor liver metastases. Dr. Soulen received Research Mentor awards from the University of Pennsylvania Department of Radiology and the North American Neuroendocrine Tumor Society and the Gold Medal from the Society of Interventional Radiology. Understanding PRRT Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training at Stony Brook University and subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty at Stanford for many years before moving to Oregon Health & Science University in 2018. Dr. Mittra is involved in all aspects of Nuclear Medicine but theranostics for oncology is of particular interest. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He is very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is a prior Medical Director of the Healing NET Foundation (HNF). Understanding the Latest in Systemic Treatments & Considerations for Treatment Sequencing Thorvardur Halfdanarson, MD Medical Oncologist, Mayo Clinic Thor R. Halfdanarson, M.D., is a medical oncologist and Professor of Oncology at Mayo Clinic who specializes in the management of patients with neuroendocrine neoplasms, gastrointestinal malignancies and unknown primary malignancies. His specific research interests include the epidemiology, risk factors and treatment of neuroendocrine tumors and neuroendocrine carcinoma and improving outcomes for pancreatic adenocarcinoma and rare types of pancreatic tumors. He is a principal investigator and co-investigator for multiple industry-sponsored and cooperative group clinical trials. Dr. Halfdanarson holds several leadership positions within Mayo Clinic Comprehensive Cancer Center. He is chair of the Hepato-Pancreatico-Biliary Cancer Disease Group and co-chair of the Pancreatic/Neuroendocrine Tumor Board. He is associate medical director of the Cancer Clinical Trials Office in Rochester, Minnesota, co-chair of the Feasibility Committee, and a member of the Clinical Research Leadership Committee. He also represents Mayo Clinic on the Neuroendocrine Tumors Guidelines Panel of the National Comprehensive Cancer Network (NCCN). Dr. Halfdanarson currently serves as President for the North American Neuroendocrine Tumor Society (NANETS). NET Tumor Board Panel: Understanding NET Liver Metastases Jaydira Del Rivero, MD Endocrinologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Eric Mittra, MD, PhD Nuclear Medicine, Oregon Health & Science University Dr. Mittra received his medical and graduate training through the MSTP (joint MD/PhD) program at Stony Brook University in New York in 2005. His master’s degree was in Anatomical Sciences, and his PhD in Biomedical Engineering. He subsequently completed a Nuclear Medicine residency and fellowship at Stanford University. He was faculty in Radiology at Stanford for 8 years, until moving to OHSU in 2018. Dr. Mittra is interested in all aspects of Nuclear Medicine imaging, therapy, and research. This includes adult and pediatric general nuclear medicine imaging with gamma camera and SPECT, PET imaging for oncology, cardiac, and neurologic applications, as well as bone densitometry (DXA imaging). Targeted Radioisotope Therapies (TRT) are of particular interest; including various applications in oncology and he is a nationally-recognized expert in this area. His research interests are primarily focused on the clinical translation of novel radioisotopes for imaging and therapy. He very involved with the Society of Nuclear Medicine and Molecular Imaging (SNMMI), the North American Neuroendocrine Tumor Society (NANETS), and is the current Medical Director of the Healing NET Foundation (HNF). Osman Ahmed, MD Interventional Radiologist, University of Chicago Osman Ahmed, MD, is an expert vascular and interventional radiologist who diagnoses and treats a wide range of conditions. Using image-guided technology and small, sophisticated instruments, Dr. Ahmed performs minimally invasive procedures for acute and chronic deep vein thrombosis, benign prostatic hyperplasia, peripheral vascular disease, liver/bone/lung/kidney cancer, spinal fractures, uterine fibroids and more. He also implants inferior vena cava (IVC) filters, which prevent a blood clot from traveling around the body or creating a blockage. In addition to his clinical expertise, Dr. Ahmed researches novel treatment options that improve outcomes for patients. His research on liver cancer, IVC filters and venous diseases has been published in several high-impact, peer-reviewed journals, including the Journal of Vascular and Interventional Radiology, Radiology, Chest, Journal of American College of Radiology, and Journal of Surgical Oncology. Dr. Ahmed also believes in the importance of educating medical students, residents, fellowships and peers in order to enhance health care across the world. He has been invited to speak at a number of symposiums, practicums and national/international meetings about the newest advancements in interventional radiology. Gangandeep Singh, MD Surgical Oncologist, City of Hope Dr. Singh is an internationally recognized liver and pancreas surgeon. He is the Chief of Surgical Oncology program, Head of the Hepatobiliary & Pancreatic Surgery Program and the Director of the Neuroendocrine Tumor Program at City of Hope Comprehensive Cancer Center (Phoenix). Dr. Singh is a seasoned leader with more than 20 years of experience building and leading several surgical teams to world-wide recognition. Dr. Singh began his faculty academic career at the Keck School of Medicine at University of Southern California (USC) in Los Angeles. From there, he was appointed as the Director of the Liver and Pancreas Center at the John Wayne Cancer Institute, Santa Monica, CA, where he also served as Chair of the Cancer Committee, and Vice President for Fellowship Education. In 2010, City of Hope (Duarte) recruited Dr. Singh to spearhead the liver and pancreatic cancer program. He was appointed Professor of Clinical Surgery and as the new Chief of the Division of Surgical Oncology (2011-2019) and hoisted their program to national recognition. He has an extensive referral base that reflects peer recognition of his clinical acumen and surgical expertise and is listed in “America’s Top Surgeons”, “Best Doctors of America”, “Super Doctors” and “Top Doctors of America.” Prior to his tenure in the Unites States, he earned is his Medical Degree from the Mahatma Gandhi Institute of Medical Sciences, India, and then trained at some of the finest cancer centers across the globe. These institutions include Tata Memorial Hospital and Cancer Center (Bombay, India), René Descartes University (Paris, France), and the Royal Liverpool University Hospital (Great Britain- England). In the USA, these institutes include the Marion Bessin Liver Center at the Albert Einstein College of Medicine (New York), Maricopa Medical Center (Phoenix), and the University of Iowa Hospitals & Clinics (Iowa City). Dr. Singh is a board-certified surgeon, a Diplomate of the American Board of Surgery and a Fellow of the American College of Surgeons. He is a member of some of the top elite surgical societies and has served as invited speaker/chair at several national and international conferences. He was a panel member of the National Comprehensive Cancer Network (NCCN) for Hepatobiliary Cancers for the last 10 years, that lays down the guidelines for the standard of care for these cancers; providing direction to both patients and physicians across the USA and the rest of the world. Dr. Singh has a very thoughtful, effective, and yet forceful approach to beating cancer, in a systematic fashion working with an outstanding multi-disciplinary team. Dynamic and compassionate, he is a skilled and an accomplished surgeon. He has extensive experience in liver and pancreatic diseases and other gastrointestinal cancers. His work is very well published with numerous publications in prestigious journals. His publications encompass complex liver resections for liver metastases, management algorithms for neuroendocrine tumors, vascular reconstructions following difficult pancreatic surgery for pancreatic cancer, and advanced robotic surgery. His work in robotic surgery has been presented on the national podium at the Society of Surgical Oncology (SSO), Americas Hepato-Pancreato-Biliary Association (AHPBA), Society of Laparoscopic & Robotic Surgeons (SLRS) and other national meetings. An innovator at heart, Dr. Singh is in constant pursuit of enhancing the surgical experience and developing technical innovations in liver and pancreatic surgery. He has collaborative endeavors with engineers from California Institute of Technology (Caltech) & Harvey Mudd College. He has several invention disclosures and patents. In addition to a large clinical practice, Dr. Singh is passionately advancing cutting-edge translational research. He collaborates with City of Hope’s molecular biologists, X-ray crystallographers, structural chemists, and super-resolution scientists. A leader who is passionate about empowering teams and individuals to achieve their full potential, Dr. Singh has been recognized with several awards and leadership positions. Understanding NET Guidelines Jaydira Del Rivero, MD Endocronologist & Medical Oncologist, National Institute of Health Dr. Del Rivero earned her medical degree from the University of Veracruz in Veracruz, Mexico and completed her internal medicine residency at Woodhull Medical and Mental Health Center/NYU-Langone Medical Center. Dr. Del Rivero completed a fellowship in Endocrinology, Diabetes and Metabolism at The Inter-Institute Endocrinology Training Program (IETP) at the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), The National Institute of Child Health and Human Development (NICHD), and The National Institute of Dental and Craniofacial Research (NIDCR) where she was part of a research team developing clinical trials for pheochromocytoma and paraganglioma. She then joined as Assistant Professor at the Montefiore Einstein Center for Cancer Care (MECCC) where she specialized in endocrine oncology involving thyroid cancer, parathyroid and adrenal tumors, and clinical research for gastroenteropancreatic neuroendocrine tumors. She subsequently completed a second fellowship in medical oncology at the National Cancer Institute (NCI) with a research focus on endocrine malignancies. Dr. Del Rivero is board certified in Internal Medicine, Endocrinology, Diabetes and Metabolism and Medical Oncology. Dr. Del Rivero is a Physician Scientist in the Developmental Therapeutics Branch. She is the Principal Investigator of the Natural History Study for Neuroendocrine Neoplasm and Adrenocortical Cancer to provide the basis of further development of therapeutic interventions, prevention/screening guidelines, endpoints for future clinical trials, and patient reported outcome measures. Dr. Del Rivero’s current efforts is the development of novel treatment approaches and targeted therapies for endocrine malignancies such as advanced gastroenteropancreatic neuroendocrine tumors, adrenocortical cancer and pheochromocytoma/paraganglioma. Understanding the Latest NET Clinical Trials Pamela Kunz, MD Medical Oncologist, Yale Medicine Dr. Pamela Kunz is an Associate Professor of Medicine in the Division of Oncology at Yale School of Medicine where she also serves as the Director of the Center for GI Cancers and Division Chief of GI Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. She received her medical degree from the Dartmouth Geisel School of Medicine. Her postgraduate training included a medical residency, chief residency, and oncology fellowship at Stanford University School of Medicine. Dr. Kunz is an international leader in the treatment and clinical research of patients with GI malignancies and neuroendocrine tumors (NETs). She holds several key leadership positions in the field including President Emeritus of the North American Neuroendocrine Tumor Society, recent past Chair of the Neuroendocrine Tumor Taskforce of the NCI and standing member of FDA’s Oncology Drug Advisory Committee. She was recently appointed Editor-in-Chief of JCO Oncology Advances. In addition to her focus on NETs, she is a leading voice for promoting diversity, equity and inclusion in medicine. She served as the Vice Chief of DEI for the Section of Medical Oncology at Yale School of Medicine and in 2021, she was awarded ‘Woman Oncologist of the Year’ by Women Leaders in Oncology for her work in promoting gender equity. MODERATORS ANDREW HENDIFAR, MD Medical Oncologist, Cedars-Sinai Medical Center The current research focus of Andrew Hendifar, MD, is on developing new therapies for pancreatic cancer and neuroendocrine tumors. Dr. Hendifar has helped form multidisciplinary teams that specialize in the treatments of pancreatic cancer, and carcinoid and neuroendocrine tumors. Dr. Hendifar is the primary investigator for several groundbreaking therapies, including radioimmunotherapy for neuroendocrine tumors, anti-inflammatory therapy for pancreatic cancer and novel approaches to cancer cachexia. His national roles include SWOG GI Committee Member and a member of NIH Neuroendocrine Tumor Task Force. He also serves as the steering committee member for the Precision Promise Consortium and chairs the associated Supportive Care Committee. At Cedars-Sinai, he leads the Gastrointestinal Disease Research Group and is the founding Director of the Hematology and Oncology Fellowship Program. DANENG LI, MD Medical Oncologist, City of Hope Daneng Li, M.D., is an associate professor in the Department of Medical Oncology & Therapeutics Research at City of Hope Comprehensive Cancer Center, specializing in treating gastrointestinal cancers. Dr. Li currently leads the liver tumors program and is also the co-director of the Neuroendocrine Tumor Program at City of Hope. Dr. Li embraces a multidisciplinary approach to treatment of patients with neuroendocrine tumors. He leads several clinical trials focused on improving outcomes for patients with NETs and works closely with scientists in the development of the next generation of novel therapeutics. Nationally, he has served on several NET committees including the NANETS Research Committee, NANETS Continuing Medical Education Committee, and the Patient-Physician Communication Task Force for the Healing NET Foundation, allowing him to work closely to support NET patient advocacy programs. For all his efforts, he was honored as a recipient of the inaugural 40 Under 40 in Cancer Award during the American Society of Clinical Oncology annual meeting in 2018. MARY DONLEVY LACNETS Board member and NET Patient Advocate Mary Donlevy joined the LACNETS Board in 2020. She brings the patient perspective as she has been thriving despite living with pancreatic neuroendocrine tumor since 2005. She has been close friends with LACNETS Founder Giovanna Joyce since 2010 and involved with LACNETS since then. Mary has served as a NET CONNECT mentor and Advisory Committee member. She has been actively involved in the monthly meetings and virtual NET support groups. Mary received her Bachelor's Degree in Communications from University of San Diego and has over 10 years of medical and sales training. Her passion is to help those dealing with this difficult diagnosis and still enjoy a very full and active life. She is the mother of four children, two of which are identical twins, born after her cancer diagnosis. Mary enjoys ocean swimming, yoga and traveling with her husband and children in her free time. Beth DeBlase NET Patient Beth was diagnosed in 2016 with metastatic, midgut NET. In that time, she has made aesthetic oncology and integrative therapies her passion. Her mission is to help enhance the quality of life for fellow cancer patients and caregivers, including herself, her four children, and husband. << Go back to the 2024 Annual Conference Page

< Back to the upcoming events page REGISTER ABOUT Join the Neuroendocrine Cancer Foundation (NCF) and Emory Winship Cancer Institute for a free, in-person educational conference designed specifically for people living with neuroendocrine cancer and their caregivers. This one-day program brings together leading experts from Emory University, the University of Alabama at Birmingham, and Vanderbilt University to provide practical, up-to-date information on the diagnosis and management of neuroendocrine cancer. Hear from local and regional neuroendocrine cancer experts as they share the latest insights in NET care, including: A multidisciplinary approach to surgery Advances in liver-directed therapy, systemic treatments, PRRT, and clinical trials Emerging research on GLP-1 agents and neuroendocrine tumors, presented by a leading scientist in the field In addition to expert-led presentations, participants will hear patient stories and have the opportunity to engage directly with specialists during live Q&A sessions. This interactive format is designed to empower patients and caregivers with knowledge, confidence, and a clearer understanding of available treatment options and care pathways. Special thanks to Dr. Udhayvir Grewal for collaborating with NCF to make this event possible. Date: Saturday, May 16, 2026 Time: 9:30 AM – 3:00 PM Eastern Location: Emory Conference Center Hotel, Atlanta, GA Cost: Free educational event for patients and caregivers Meals: Breakfast and lunch provided This event is made possible by the generosity of donors and sponsors. LOCATION Starvine Ballroom, Emory Conference Center Hotel 1615 Clifton Rd N E, Atlanta, GA 30329 AGENDA *Subject to change. Please check back closer to the event for the most accurate agenda. SPEAKER BIOS Time Topic Speaker 9:00 - 9:50 AM Registration & Breakfast 9:50 - 10:05 AM Welcome Neuroendocrine Cancer Foundation Team & Dr. Udhayvir Grewal 10:05 - 10:10 AM Patient Story 10:10 - 10:25 AM Multidisciplinary Approach to Surgery for NET Dr. Seth Concors 10:25 - 10:40 AM Liver-Directed Therapy: Understanding Minimally Invasive Options to Treat Liver Tumors Dr. Meghan A. Lilly 10:40 - 10:55 AM Understanding Your Scans and PRRT: How Imaging Guides Treatment Dr. Heather Cole 10:55 - 11:10 AM Preparing for PRRT: What Patients Need to Know Dr. Saima Muzahir 11:10 - 11:25 AM Systemic Therapy for Neuroendocrine Cancer: What Patients Need to Know Dr. Garima Gupta 11:25 AM - 12:15 PM Q & A with Expert Panel Concors, M.D., Gupta, M.D., Muzahir, M.D., Cole, M.D. 12:15 - 1:15 PM Lunch 1:15 - 1:35 PM How Do GLP-1 Agents Factor Into Neuroendocrine Tumor Care Strategies? Po Hien Ear, PhD 1:35 - 1:50 PM What It Means To Be Part of a Clinical Trial Dr. Daniel Halperin 1:50 - 2:10 PM Clinical Trials: What's on the Horizon? Dr. Udhayvir Grewal 2:10 - 2:55 PM Q & A with Expert Panel Ear, PhD, Halperin, M.D., Grewal, M.D. 2:55 - 3 PM Closing The opinions expressed by the guest presenters, as well as the questions asked by the audience, have not been created or suggested by NCF or the sponsors of this program. NCF does not endorse or promote any of the views, opinions or information provided in this presentation. Audience members should not rely solely on the opinions or information expressed by the guest presenter and should seek guidance and direction from their own medical advisors regarding any choices they make about their health or treatments. THANKS TO OUR SPONSORS

“Luncheon With The Experts” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. LUNCHEON WITH THE EXPERTS “Luncheon With The Experts” is a recurring educational outreach series (previously hosted by the Carcinoid Cancer Foundation) aimed at patients, caregivers, and the broader neuroendocrine cancer community. The sessions are hosted by Rain Bennett. The series features medical specialists — oncologists, surgeons, researchers, and other clinical experts — who present on topics relevant to neuroendocrine cancer and answer audience questions live via chat. Programs are typically delivered live (over Facebook Live and YouTube Live) at noon Eastern Time, allowing participants to join with their lunch break. Live sessions are recorded and will be available after the live event. Dr. Boris G. Naraev Dr. Naraev is a board-certified medical oncologist at the Tampa General Hospital’s Cancer Institute, specializing in caring for people living with neuroendocrine and endocrine tumors. He is an Associate Professor of Medicine at the Division of Hematology and Medical Oncology of the University of South Florida, Morsani College of Medicine. Visit the Event Page

Clinical Trials Guide What’s Going On With Clinical Trials By type of disease or treatment Browse by Trial How to Use Our Clinical Trials Guide Ancora.ai Clinical Trial Finder What’s Going On With Clinical Trials Clinical Trials News Play Video Play Video 06:31 Update on Cabozantinib Neuroendocrine Cancer Foundation Interview with Dr. Aman Chauhan • 2025 Clarification: The recent CABINET subgroup analysis presented at ESMO included thoracic NET patients (lung and thymic), with approximately 80% being lung NETs. Additionally, in the epNET cohort, about 20% of patients had lung NETs. Learn about one of the biggest breakthroughs in neuroendocrine tumor (NET) treatment: the FDA approval of Cabozantinib for metastatic NETs. In this in-depth interview, the Neuroendocrine Cancer Foundation’s Lisa Yen speaks with NET expert Dr. Aman Chauhan about the landmark CABINET clinical trial, new data from ESMO 2025, and what this means for patients with pancreatic NETs, extra-pancreatic NETs, lung NETs, and thymic NETs. Dr. Chauhan explains why Cabozantinib—a VEGF TKI targeted therapy—is transforming care for patients who often have limited treatment options, especially those with somatostatin receptor–negative lung NETs who may not qualify for somatostatin analogs (SSA) or PRRT. He also discusses promising results in higher-grade (G2–G3) well-differentiated NETs, an area with few effective treatment choices. ✔ What the CABINET trial revealed ✔ Why Cabozantinib is effective across multiple NET types ✔ How lung and thymic NET patients (thoracic NETs) benefited—~80% of the thoracic subgroup were lung NETs ✔ How this approval is changing clinical practice ✔ Introduction to Zanzalintinib (Zanza) — a next-generation VEGF TKI now entering phase 3 trials ✔ How to find NET clinical trials near you on ClinicalTrials.gov If you’re a patient, caregiver, or healthcare professional looking for new NET treatment options, this update provides essential insights into where the field is headed and how future drugs are being developed. 🔗 Search for NET clinical trials: https://www.ncf.net/clinical-trials Play Video Play Video 04:02 The Latest Advances in Neuroendocrine Cancer: An Update with Dr. Udhayvir Grewal • 2025 In this conversation, Dr. Udhayvir Grewal from the Winship Cancer Institute at Emory shares the newest developments in neuroendocrine cancer (NET/NEC) research, treatment, and clinical trials — offering clarity, progress updates, and hope for patients and caregivers in the NET community. 🔬 Key Highlights: - Alpha PRRT (Alpha Radioligand Therapy): New investigational treatments including Lead-212 Dotamtate, Lead-212 VMT-Alpha-NET, and Actinium-225 Dotatate (ACTION-1) are showing promising early results and may change the treatment landscape for NET patients. - New FDA-Approved Therapy for Pheochromocytoma & Paraganglioma: Belzutifan is now available for a subset of patients, supported by durable response data from the LITESPARK study. - Advances in High-Grade Neuroendocrine Carcinoma: Encouraging results are emerging from trials targeting DLL3, including obrixtamig, radioligand therapies, ADCs, and tri-specific drugs currently in development. 📍 Next Steps & Resources To explore active clinical trials and educational resources, visit: 🔗 NCF.net #NeuroendocrineCancer #NETCancer #NeuroendocrineTumor #CancerResearch #PRRT #ClinicalTrials #PatientEducation #NCF #NETUpdates #AlphaPRRT #DLL3 Play Video Play Video 06:26 The Latest in High-Grade Neuroendocrine Carcinoma (NEC): A Conversation with Dr. Chauhan • 2025 In this important update, Dr. Aman Chauhan shares the newest and most promising developments in treatment and research for high-grade neuroendocrine carcinoma (NEC) — a rare and aggressive form of neuroendocrine cancer. For decades, treatment options for NEC have been limited and outcomes have remained largely unchanged. Today, that reality is beginning to shift — and this conversation highlights the progress bringing renewed hope to patients and families. Highlights in This Discussion: - DLL3-targeted immunotherapy, including T-cell engagers such as tarlatamab and emerging therapies like Obrixtamig - Ongoing progress in clinical trials for high-grade NEC - Early success with radiopharmaceutical approaches targeting DLL3 - Exploration of oncolytic viruses, including the Seneca Valley Virus combined with ipilimumab (ipi) and nivolumab (nivo) - Advances in next-generation immunotherapy, including CAR-T and checkpoint combinations 📍 Want to Learn More? To explore active or upcoming clinical trials for NEC, visit the Neuroendocrine Cancer Foundation’s Clinical Trials Guide at NCF.net/clinical-trials #NeuroendocrineCancer #NEC #HighGradeNEC #ClinicalTrials #Immunotherapy #DLL3 #PatientEducation #NETCancer #NeuroendocrineTumor #CancerResearch #NCF Play Video Play Video 06:20 Dr. Jennifer Chan Shares 2025 Highlights & Future Directions in NET Research at the 2025 INCA Summit In this exclusive 2025 INCA Summit interview, Lisa Yen from the Neuroendocrine Cancer Foundation speaks with Dr. Jennifer Chan, President of NANETS and medical oncologist at Dana-Farber Cancer Institute, about the latest advances and future directions in neuroendocrine cancer research and treatment. Dr. Chan reflects on her 20-year journey in the field and highlights a pivotal year for neuroendocrine cancer care — including the FDA and EMA approvals of cabozantinib for both pancreatic and extrapancreatic NETs, and belzutifan for advanced pheochromocytomas and paragangliomas. She discusses how these breakthroughs are expanding treatment options and offering renewed hope to patients worldwide. Looking ahead, Dr. Chan shares her excitement about ongoing and upcoming clinical trials, including the COMPETE trial (PRRT vs. everolimus) and studies involving alpha-emitting PRRT agents, which may further transform clinical practice. 🎥 Highlights: Global collaboration through the International Neuroendocrine Cancer Alliance (INCA) Major new treatment approvals in 2025 (cabozantinib, belzutifan) Promising data from recent and emerging clinical trials (COMPETE, PRRT advances) A look toward the next wave of neuroendocrine cancer research 📍 Recorded live at the 2025 INCA Summit in Sofia, Bulgaria 👩⚕️ Guest: Dr. Jennifer Chan, President of NANETS 🎙️ Host: Lisa Yen, Neuroendocrine Cancer Foundation #NeuroendocrineCancer #INCA2025 #NANETS #Cabozantinib #Belzutifan #DanaFarber #OncologyResearch #PatientAdvocacy Play Video Play Video 05:29 Dr. Jennifer Chan & Dr. Del Rivero Discuss Advancing NET Research at the 2025 INCA Summit In this insightful conversation from the 2025 INCA Summit in Sofia, Bulgaria, leading neuroendocrine cancer experts Dr. Jennifer Chan (Dana-Farber Cancer Institute, USA) and Dr. Jaydira Del Rivero (National Cancer Institute, NIH) discuss the future of neuroendocrine tumor (NET) research, emphasizing the importance of clinical trials, patient engagement, and international collaboration. Dr. Del Rivero highlights the mission of INCA’s research committee—to align scientific priorities with patient needs, ensure greater patient participation in research, and develop better models and biomarkers for understanding and treating NETs. She explains the range of clinical research, from translational and molecular studies to natural history, prevention, and treatment trials, and how each contributes to improving diagnosis, therapy, and quality of life for patients. Dr. Chan underscores the vital role of patients as partners in research, helping shape meaningful endpoints and driving practice-changing discoveries like the CABINET trial, which recently led to new treatment approvals for neuroendocrine cancers. 🎥 Highlights: The mission of the INCA Research Committee Translational research and model development for NETs The value of biomarkers and molecular insights Understanding natural history studies and their role in cancer discovery Empowering patients as research partners Reflections on the impact of the CABINET study 📍 Recorded live at the 2025 International Neuroendocrine Cancer Alliance (INCA) Summit, Sofia, Bulgaria 👩⚕️ Speakers: Dr. Jennifer Chan & Dr. Jaydira Del Rivero #NeuroendocrineCancer #INCA2025 #ClinicalTrials #CancerResearch #PatientAdvocacy #DanaFarber #NIH #NANETS #CABINETTrial #OncologyResearch Play Video Play Video 05:30 Dr. Halfdanarson on ITM’s COMPETE Trial • 2025 ENETS • Neuroendocrine Cancer Foundation NANETS President Emeritus Dr. Thor Halfdanarson discussed the positive results from ITM’s Phase 3 COMPETE Trial at the 2025 ENETS Annual Medical and Scientific Conference in Krakow, Poland. The COMPETE trial was the first prospective, randomized phase 3 study comparing PRRT with an active treatment (everolimus or afinitor). For more information, visit https://www.ncf.net/clinical-trials. Play Video Play Video 05:27 Dr. Jennifer Chan Discusses Results of CABINET Trial (Cabozantinib) as Effective Treatment at ESMO24 Watch #LACNETS' exclusive view with incoming NANETS president Dr. Jennifer Chan at ESMO Congress 2024 (#ESMO24) in Barcelona, Spain, explaining the updated results of the CABINET trial evaluating Cabozantinib in Advanced Neuroendocrine Tumors. https://www.lacnets.org/post/positive-results-of-the-cabinet-trial-show-cabozantinib-as-a-new-effective-treatment-in-advanced-n Play Video Play Video 04:44 Dr. Aman Chauhan About the Most Exciting Progress in the Neuroendocrine Cancer Field @ NANETS Miami In this exclusive interview at NANETS Regional in Miami, NET expert Dr. Aman Chauhan from Sylvester Comprehensive Cancer Center shares the recent advances he's most excited about in the neuroendocrine cancer field. @SylvesterCancer @AmanChauhanMD @CarcinoidNETs @HealingNET1 @netcancerday @CureNETs @PheoPara #NETsMiami Breaking News: NETTER-2 Trial Supports Lutathera® as 1st Line Treatment >>> Dr. Jennifer Chan Announces the CABINET Trial Data on Cabozantinib >>> Interviews With Experts By type of disease or treatment Browse Clinical Trials by Type of Disease or Treatment: Additional Resources Click Here G3 Neuroendocrine Neoplasms (NEN) or High Grade Click Here Immunotherapy Click Here NIH/NCI Natural History Study for Neuroendocrine Neoplasms Click Here PRRT/Radioligand Therapy (RLT) Click Here Pheochromocytoma/ Paraganglioma Click Here Surgery Trials Click Here Carcinoid Syndrome Click Here Gastrointestinal (GI) NETs Click Here Lung/Bronchial NETs Click Here Other Click Here Pancreatic NET (PNET) Click Here Somatostatin Analogue (SSA) Click Here Targeted Therapies Click Here IN-DEPTH LOOK: CLINICAL TRIALS Research / Clinical Trials Play Video Play Video 06:46 (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET • ClinicalTrials.gov ID: NCT06943755 Dr. Aman Chauhan discusses (STELLAR-311) Zanzalintinib Versus Everolimus in pNET and epNET with Locally Advanced or Metastatic Neuroendocrine Tumors. Visit https://www.ncf.net/clinical-trials for more information. Play Video Play Video 14:15 Tarlatamab in DLL3-Expressing Tumors Including NEN • ClinicalTrials.gov: NCT06788938 • Dr. Goldman Join Dr. Jonathan Goldman, medical oncologist and clinical trial specialist at UCLA, as he provides an in-depth overview of a new clinical trial investigating tarlatumab, a DLL3-targeted bispecific T-cell engager designed to treat a wide range of neuroendocrine tumors (NETs) and neuroendocrine carcinomas (NECs). In this talk, Dr. Goldman explains: - What DLL3 is and why it is an important target found on many neuroendocrine tumors - How tarlatumab works by connecting T-cells to tumor cells to trigger a focused immune response - Why DLL3-positive tumors—including small cell lung cancer, lung carcinoids, thymic tumors, pancreatic NETs, gastrointestinal NETs, prostate NEC, Merkel cell carcinoma, and others—may respond to this therapy - The structure of the L10 Clinical Trial, now in Stage 2 and enrolling across all University of California cancer centers - What patients can expect from the tarlatumab treatment schedule and dosing - Potential side effects such as cytokine release syndrome, fatigue, constipation, loss of taste, neurologic symptoms, and tumor lysis syndrome Dr. Goldman highlights both the promise of DLL3-targeted therapies and the ongoing need to understand how DLL3 expression levels relate to patient response. For more information, visit https://www.ncf.net/clinical-trials-1/tarlatamab Play Video Play Video 13:57 A Study of ZL-1310 in Participants With Selected Solid Tumors • ClinicalTrials.gov ID: NCT06885281 Dr. Rohit Thummalapalli discusses "A Study of ZL-1310 in Participants With Selected Solid Tumors" (ClinicalTrials.gov ID: NCT06885281). For more information, visit NCF.net/clinical-trials Play Video Play Video 06:54 (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen•NCT07087054 Dr. Aman Chauhan discusses (CAREFNDR) Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen (ClinicalTrials.gov: NCT07087054). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 08:57 Study of 225Ac-ABD147 to Establish Optimal Dose • ClinicalTrials.gov: NCT06736418 • Dr. Chauhan Dr. Aman Chauhan discusses the Study of 225Ac-ABD147 to Establish Optimal Dose in Patients With SCLC and LCNEC of the Lung That Previously Received Platinum-based Chemotherapy (ClinicalTrials.gov: NCT06736418). For more information, visit https://www.ncf.net/clinical-trials Play Video Play Video 12:34 May 19, 2025: Dr. Aman Chauhan discusses the DAREON-5 & DAREON-7 Studies DAREON-5 is a phase 2 trial studying BI 764532, an antibody-like molecule (DLL3/CD3 bispecific) that may help the immune system fight cancer. This is a clinical trial for high grade neuroendocrine cancers. It is open to adults with small cell lung cancer and other neuroendocrine cancers including extra-pulmonary neuroendocrine carcinoma and large cell neuroendocrine carcinoma. The purpose of the study is to find a suitable dose of BI 764532. The study is sponsored by Boehringer Ingelheim. For more information, visit https://www.lacnets.org/clinical-trials-1/dareontm--5%3A-dll-3-bite-for-neuroendocrine-cancers. Play Video Play Video 16:57 SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated NEC or Well-Differentiated High-Grade NET Dr. Aman Chauhan at the Sylvester Comprehensive Cancer Center, University of Miami, discusses SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) tumors. Recorded: April 22, 2025 For more information, visit https://www.ncf.net/clinical-trials-1/svv-001 Play Video Play Video 29:35 IL13Rα2 CAR T Cell Study for Solid Tumor Cancers • Dr. Anusha Kalbasi Dr. Anusha Kalbasi from Stanford discusses the immunotherapy study using IL13Rα2 CAR T cell for the treatment of metastatic solid tumors on March 27, 2024. For more information about this trial, visit https://www.lacnets.org/clinical-trials-1/il13r%CE%B12-car-t-cell-study-for-solid-tumor-cancers. Visit the LACNETS Clinical Trials page for more information at https://www.lacnets.org/clinical-trials. Browse by Trial: 225Ac-ABD147 to Establish Optimal Dose in SCLC and LCNEC ACTION-1: Alpha PRRT with Ac-225 in GEP-NETs ALPHAMEDIX: Alpha PRRT with Pb-212 DOTAMTATE in NETs Alpha PRRT with Ac-225 + Standard of Care in SSTR+ SCLC Alpha PRRT with Pb-212 VMT Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors and Carcinomas Belzutifan-MK-6482 in PNET + PPGL + VHL BRAVESST2: CRN09682 in SST2-Expressing NENs and Other Solid Tumors CABINET: Cabozantinib in Advanced pNET and Carcinoid Tumors CAREFNDR: Carcinoid Syndrome Efficacy Study Featuring an Oral Daily Paltusotine Regimen CDK4/6 Abemaciclib GEP-NETS CHM-2101 CAR-T cell for GI Cancers ComPareNET: Lu-177 DOTATATE vs CAPTEM in Advanced pNETs COMPOSE: PRRT with Lu-177 EDOTREOTIDE versus “Standard of Care” in Well-Differentiated Aggressive G2 & G3 GEP-NETS DAREON™- 5: DLL-3 BiTE for Neuroendocrine Cancers DAREON™-7: DLL-3 for Advanced Neuroendocrine Cancers DAREON™-9: DLL-3 BiTE + Topotecan in Small Cell Lung Cancer (SCLC) IDE849 (DLL3-targeted ADC) ± durvalumab in DLL3+ tumors IL13Rα2 CAR T Cell Study for Solid Tumor Cancers LAMPARA: LAnreotide in Metastatic Pheochromocytoma/PARAganglioma Lu-177 + Carboplatin, Etoposide, and Atezolizumab in SCLC Lu-177 DOTATATE + Cabozantanib in NETs Lu-177 DOTATATE vs Everolimus in Lung NETs Lu-177 DOTATATE + M3814 (Peposertib) in GEP-NETs Lu-177 DOTATATE + Olaparib in GEP-NETs Lu-177 DOTATATE + Sunitinib in PNETs Lu-177 DOTATATE + Triapine in GEP-NETs Nab-sirolimus in Patients With Well-differentiated Neuroendocrine Tumors (NETs) Tissue Procurement and Natural History Study of Neuroendocrine Neoplasms (NENs) Including Adrenocortical Carcinoma (ACC) NET RETREAT: Retreatment with 177Lu-DOTATATE vs Everolimus in Metastatic Midgut NET NETTER-P: Lutathera in Adolescent Patients (12-17) with GEP-NETs and PPGLs Olaparib + Usual Chemotherapy (Temozolomide) in PPGL Paltusotine in Carcinoid Syndrome RYZ401: Alpha PRRT with RYZ401 in PRRT-naive Solid Tumors Expressing SSTR SORENTO™: Subcutaneous Octreotide for GEP-NETs (Cam2029) STELLAR-311: Zanzalintinib Versus Everolimus in pNET and epNET Survivin Long Peptide Vaccine (SurVaxM) in Metastatic NETs SVV-001 + Ipi-Nivo in Patients With Poorly Differentiated (NEC) or Well-Differentiated High-Grade (NET) SWOG S2104: Adjuvant CAPTEM for High Risk pNET SWOG S2012: Immunotherapy (Atezolizumab) + Standard Platinum Chemotherapy for NEC SWOG 2408: Lanreotide vs Placebo Before Surgery to Prevent Pancreatic Fistula Systemic VSV-IFNβ-NIS and Pembrolizumab in Refractory NSCLC and NEC Tarlatamab in DLL3-Expressing Tumors Including Neuroendocrine Neoplasms upLIFT: Ersodetug in Insulinoma/Tumor Hyperinsulinism ZL-1310 (DLL3-targeted ADC) in DLL3+ Tumors Browse by Trial UNDERSTANDING CLINICAL TRIALS Finding and learning more about relevant neuroendocrine cancer clinical trials may feel overwhelming. While comprehensive databases are available to search for trials, it may be difficult to understand whether a trial is right for you. Our goal is to offer a resource with key, open clinical trials for those with neuroendocrine cancer (aka, neuroendocrine neoplasm or NEN, including neuroendocrine tumor or NET and neuroendocrine carcinoma or NEC). We hope this information will help you better understand clinical trials and empower you to discuss them with your medical team. You may browse the Clinical Trials Guide in the following ways: Browse by selecting a type of disease or treatment. For example, if you are interested in open trials for pancreatic neuroendocrine tumor (PNET), click on the “PNET” image below. If you are interested in exploring peptide receptor radionuclide therapy (PRRT) trials, click on the “PRRT” image below. Browse by the trial using the table of contents. Click on individual trials to learn more information. Use the Ancora.ai clinical trial finder by entering your location and specifics about your tumor to find appropriate clinical trials. Then, browse this clinical trial guide to learn more about the suggested trials. When exploring the Clinical Trials Guide, you will find a description of each trial and contact information. Many also include a video of a NET expert describing the trial. The videos explain the study and who is eligible to participate. You can consider clinical trials at any time during your NET journey. Options range from first-line treatments for those newly diagnosed to novel treatments for those who have already had multiple treatments. For more information on how your involvement may benefit you and the NET community, read Why Participate in Clinical Trials . Download "Glossary of Common Terms in Clinical Trials" >>> Download "Clinical Trials: How to Prepare" >>> How to Use Our Clinical Trials Guide Ancora.ai Clinical Trial Finder Ancora.ai Ancora.ai is a neuroendocrine tumor clinical trial finder for patients and physicians developed by Ancora.ai and NorCalCarciNET. Ancora allows you to do a personalized search, filter and export results, and if interested, Ancora's patient team can help connect you to a trial site to begin the evaluation process. It's free and easy to use. Click here to access Ancora.ai >> DISCLAIMER: This information is for educational purposes only. The Neuroendocrine Cancer Foundation encourages you to discuss your individual care and treatment options with your medical team. The Neuroendocrine Cancer Foundation does not endorse any particular trial or treatment. This is not a complete list of available NET trials nor is it intended to be. For comprehensive information about available clinical trials, go to ClinicalTrials.Gov.